<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id>
<journal-title-group>
<journal-title>Orphanet Journal of Rare Diseases</journal-title>
</journal-title-group>
<issn pub-type="epub">1750-1172</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30808424</article-id>
<article-id pub-id-type="pmc">6390566</article-id>
<article-id pub-id-type="publisher-id">1025</article-id>
<article-id pub-id-type="doi">10.1186/s13023-019-1025-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Congenital myasthenic syndromes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Finsterer</surname>
<given-names>Josef</given-names>
</name>
<address>
<phone>+43-1-71165-72085</phone>
<email>fifigs1@yahoo.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9686 6466</institution-id><institution-id institution-id-type="GRID">grid.6583.8</institution-id><institution>Krankenanstalt Rudolfstiftung, </institution><institution>Messerli Institute, Veterinary University of Vienna, </institution></institution-wrap>Postfach 20, 1180 Vienna, Austria </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>26</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>26</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<elocation-id>57</elocation-id>
<history>
<date date-type="received">
<day>8</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Objectives</title>
<p id="Par1">Congenital myasthenic syndromes (CMSs) are a genotypically and phenotypically heterogeneous group of neuromuscular disorders, which have in common an impaired neuromuscular transmission. Since the field of CMSs is steadily expanding, the present review aimed at summarizing and discussing current knowledge and recent advances concerning the etiology, clinical presentation, diagnosis, and treatment of CMSs.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">Systematic literature review.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">Currently, mutations in 32 genes are made responsible for autosomal dominant or autosomal recessive CMSs. These mutations concern 8 presynaptic, 4 synaptic, 15 post-synaptic, and 5 glycosilation proteins. These proteins function as ion-channels, enzymes, or structural, signalling, sensor, or transporter proteins. The most common causative genes are CHAT, COLQ, RAPSN, CHRNE, DOK7, and GFPT1. Phenotypically, these mutations manifest as abnormal fatigability or permanent or fluctuating weakness of extra-ocular, facial, bulbar, axial, respiratory, or limb muscles, hypotonia, or developmental delay. Cognitive disability, dysmorphism, neuropathy, or epilepsy are rare. Low- or high-frequency repetitive nerve stimulation may show an abnormal increment or decrement, and SF-EMG an increased jitter or blockings. Most CMSs respond favourably to acetylcholine-esterase inhibitors, 3,4-diamino-pyridine, salbutamol, albuterol, ephedrine, fluoxetine, or atracurium.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">CMSs are an increasingly recognised group of genetically transmitted defects, which usually respond favorably to drugs enhancing the neuromuscular transmission. CMSs need to be differentiated from neuromuscular disorders due to muscle or nerve dysfunction.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Myasthenic syndrome</kwd>
<kwd>Myasthenia</kwd>
<kwd>Repetitive nerve stimulation</kwd>
<kwd>Fatigue</kwd>
<kwd>Weakness</kwd>
<kwd>Hereditary</kwd>
<kwd>Genes</kwd>
<kwd>Mutation</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>none</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par31">Congenital myasthenic syndromes (CMS) are a heterogeneous group of early-onset genetic neuromuscular transmission disorders due to mutations in proteins involved in the organisation, maintenance, function, or modification of the motor endplate (endplate myopathies) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). CMS are clinically characterised by abnormal fatigability, or transient or permanent weakness of extra-ocular, facial, bulbar, truncal, respiratory, or limb muscles. Onset of endplate myopathy is intrauterine, congenital, in infancy, or childhood, and rarely in adolescence. Severity ranges from mild, phasic weakness, to disabling, permanent muscle weakness, respiratory insufficiency, and early death. All subtypes of CMS share the clinical features of fatigability and muscle weakness, but age of onset, presenting symptoms, and response to treatment vary depending on the molecular mechanism that results from the underlying genetic defect. The term CMS is misleading since not all CMS are congenital.</p>
<p id="Par32">Aims of the present review were to summarise and discuss previous and recent findings concerning the genotype, phenotype, diagnosis, treatment, and outcome of CMS.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<p id="Par33">Data for this review were identified by searches of MEDLINE for references of relevant articles. Search terms used were “congenital myasthenic syndrome”, “endplate”, or “mutation”, combined with all gene names so far associated with CMS. Results of the search were screened for potentially relevant studies by application of inclusion and exclusion criteria for the full texts of the relevant studies. Randomized controlled trials (RCTs), observational studies with controls, case series, and case reports were included. Only original articles about humans, and published between 1966 and 2017 were included. Reviews, editorials, and letters were not considered. Reference lists of retrieved studies were checked for reports of additional studies. Websites checked for additional, particularly genetic information and for assessing the pathogenicity of CMS mutations were the following:</p>
<p id="Par34">Neuromuscular homepage: <ext-link ext-link-type="uri" xlink:href="https://neuromuscular.wustl.edu/">https://neuromuscularwu.stl.edu/</ext-link></p>
<p id="Par35">Genetics home reference: <ext-link ext-link-type="uri" xlink:href="https://ghr.nlm.nih.gov/condition/congenital-myasthenic-syndrome">https://ghr.nlm.nih.gov/condition/congenital-myasthenic-syndrome</ext-link></p>
<p id="Par36">National Organisation for Rare Disorders: <ext-link ext-link-type="uri" xlink:href="https://rarediseases.org/rare-diseases/congenital-myasthenic-syndromes">https://rarediseases.org/rare-diseases/congenital-myasthenic-syndromes</ext-link>/.</p>
</sec>
<sec id="Sec3">
<title>Results</title>
<sec id="Sec4">
<title>History</title>
<p id="Par37">The first case of a patient with CMS was reported in 1977 by Engel et al. [<xref ref-type="bibr" rid="CR3">3</xref>]. The first mutation associated with CMS was reported in the <italic>CHRNE</italic> gene by Gomez et al. in 1995 [<xref ref-type="bibr" rid="CR4">4</xref>]. The first molecular genetic defect resulting in a presynaptic congenital myasthenic syndrome has been reported by Ohno in 2001 [<xref ref-type="bibr" rid="CR5">5</xref>]. Detection dates of mutations in any of the 32 CMS genes reported in the literature are listed in Table <xref ref-type="table" rid="Tab1">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Scheme of the main pathophysiological mechanisms involved in CMS: (1) acetylcholine biosynthesis defects and vesicular transport and fusion defects; (2) AchE deficiency; (3) AchR defects; (4) agrin deficiency; (5) disorders of glycosylation; (6) channelopathies; (7) myopathies with secondary neuromuscular transmission defects; and (8) mitochondrial dysfunction; ChAT: choline acetyltransferase; ErbBR: epidermal growth factor receptor; MASC: muscle-associated specificity component; Lrp4: low-density lipoprotein receptor-related protein 4 [reproduced from Sousa et al. Arq Neuropsquiatr 2016;74:750 [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR143">143</xref>] [permission applied]</p></caption><graphic id="MO1" xlink:href="13023_2019_1025_Fig1_HTML"></graphic></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>First reports of mutations in any of the 32 CMS genes [<xref ref-type="bibr" rid="CR142">142</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Year of first report</th><th>NOPR#</th><th>Reference for 1st description</th></tr></thead><tbody><tr><td>COLQ</td><td>1998</td><td>&gt; 115</td><td>[<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td>CHRNE</td><td>2000</td><td>97</td><td>[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td>CHAT</td><td>2001</td><td>46</td><td>[<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr><tr><td>SCN4A</td><td>2003</td><td>3</td><td>[<xref ref-type="bibr" rid="CR96">96</xref>]</td></tr><tr><td>RAPSN</td><td>2003</td><td>84</td><td>[<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td>MUSK</td><td>2004</td><td>9</td><td>[<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td>CHRND</td><td>2006</td><td>4</td><td>[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td>CHRNG</td><td>2006</td><td>17</td><td>[<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td>DOK7</td><td>2006</td><td>&gt; 50</td><td>[<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td>CHRNA1</td><td>2008</td><td>6</td><td>[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td>LAMB2</td><td>2009</td><td>1</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td>AGRN</td><td>2009</td><td>12</td><td>[<xref ref-type="bibr" rid="CR140">140</xref>]</td></tr><tr><td>CHRNB1</td><td>2010</td><td>3</td><td>[<xref ref-type="bibr" rid="CR10">10</xref>]</td></tr><tr><td>PLEC1</td><td>2010</td><td>3</td><td>[<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td>GFPT1</td><td>2011</td><td>29</td><td>[<xref ref-type="bibr" rid="CR141">141</xref>]</td></tr><tr><td>DPAGT1</td><td>2012</td><td>12</td><td>[<xref ref-type="bibr" rid="CR124">124</xref>]</td></tr><tr><td>ALG2</td><td>2013</td><td>5 + 1 family</td><td>[<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td>ALG14</td><td>2013</td><td>7</td><td>[<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td>LRP4</td><td>2014</td><td>3</td><td>[<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td>PREPL</td><td>2014</td><td>1</td><td>[<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td>SNAP25</td><td>2014</td><td>1</td><td>[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td>SYT2</td><td>2014</td><td>2 families</td><td>[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td>SLC25A1</td><td>2014</td><td>3</td><td>[<xref ref-type="bibr" rid="CR107">107</xref>]</td></tr><tr><td>COL13A1</td><td>2015</td><td>3</td><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td>GMPPB</td><td>2015</td><td>13</td><td>[<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td>SLC18A3</td><td>2016</td><td>3 families</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>SLC5A7</td><td>2016</td><td>7 families</td><td>[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td>MYO9A</td><td>2016</td><td>3</td><td>[<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td>MUNC13–1</td><td>2016</td><td>1</td><td>[<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td>VAMP1</td><td>2017</td><td>4</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td>LAMA5</td><td>2017</td><td>1</td><td>[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td>SYB1</td><td>2017</td><td>1</td><td>[<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr></tbody></table><table-wrap-foot><p>NOPR: number of patients/families reported so far, #: since first description (some figures may be imprecise since reporting of patients may overlap between publications)</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec5">
<title>Classification</title>
<p id="Par38">CMS may be classified according to various different criteria. According to the mode of inheritance, CMS may be classified as autosomal dominant (AD), autosomal recessive (AR), as de novo, or as either AD or AR [<xref ref-type="bibr" rid="CR6">6</xref>]. CMS can be also classified according to the mutated protein (Table <xref ref-type="table" rid="Tab2">2</xref>). Following this classification criterion, 32 different types of CMS can be currently differentiated (Table <xref ref-type="table" rid="Tab2">2</xref>). A third scheme differentiates CMS due to a presynaptic, synaptic or post-synaptic pathology. A fourth category refers to CMS due to glycosylation defects. Furthermore, CMS may be classified according to the function of the mutated protein (e.g. enzyme, structural protein, pore protein). Another possibility to classify CMS is the type of mutation such as point mutations (missense or truncating (frameshift, splice site, nonsense)), deletions, duplications, indels, or insertions. According to the long-term course, CMS may be classified as progressive, fluctuating, or regressive [<xref ref-type="bibr" rid="CR7">7</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Genes mutated in CMS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Chromosome</th><th>MOI</th><th>LD</th><th>OOCM</th><th>PCMS (%)<sup>a</sup></th></tr></thead><tbody><tr><td>AGRN</td><td>1p36.33</td><td>AR</td><td>post</td><td>con, inf</td><td>&lt; 1</td></tr><tr><td>ALG2</td><td>9q22.33</td><td>AR</td><td>glyc</td><td>con, inf</td><td>&lt; 1</td></tr><tr><td>ALG14</td><td>1p21.3</td><td>AR</td><td>glyc</td><td>con, child</td><td>&lt; 1</td></tr><tr><td>CHAT</td><td>10q11.23</td><td>AR</td><td>pre</td><td>con, inf</td><td>4–5</td></tr><tr><td>CHRNA1</td><td>2q31.1</td><td>AD/AR</td><td>post</td><td>con, adult</td><td>&lt; 1</td></tr><tr><td>CHRNB1</td><td>17p13.1</td><td>AF/AR</td><td>post</td><td>inf</td><td>&lt; 1</td></tr><tr><td>CHRND</td><td>2q37.1</td><td>AD/AR</td><td>post</td><td>inf</td><td>&lt; 1</td></tr><tr><td>CHRNE</td><td>17p13.2</td><td>AD/AR</td><td>post</td><td>con, inf, child, adult</td><td>50</td></tr><tr><td>CHRNG</td><td>2q37.1</td><td>AR</td><td>post</td><td>con</td><td>uk</td></tr><tr><td>COL13A1</td><td>10q22.1</td><td>AR</td><td>post</td><td>con</td><td>&lt; 1</td></tr><tr><td>COLQ</td><td>3p24.2</td><td>AR</td><td>syn</td><td>con, inf, child</td><td>10–15</td></tr><tr><td>DOK7</td><td>4p16.3</td><td>AR</td><td>post</td><td>con, inf, child, adol, adult</td><td>10–15</td></tr><tr><td>DPAGT1</td><td>11q23.3</td><td>AR</td><td>glyc</td><td>inf, adol</td><td>&lt; 1</td></tr><tr><td>GFPT1</td><td>2p13.3</td><td>AR</td><td>glyc</td><td>con, inf, child, adult</td><td>2</td></tr><tr><td>GMPPB</td><td>3p21.31</td><td>AR</td><td>glyc</td><td>con</td><td>&lt; 1</td></tr><tr><td>LAMA5</td><td>20q13.33</td><td>uk</td><td>pre</td><td>con</td><td>&lt; 1</td></tr><tr><td>LAMB2</td><td>3p21.31</td><td>AR</td><td>syn</td><td>con</td><td>&lt; 1</td></tr><tr><td>LRP4</td><td>11p11.2</td><td>AR</td><td>post</td><td>con</td><td>&lt; 1</td></tr><tr><td>MUNC13–1</td><td>19</td><td>AR</td><td>pre</td><td>inf</td><td>&lt; 1</td></tr><tr><td>MUSK</td><td>9q31.3</td><td>AR</td><td>post</td><td>con</td><td>&lt; 1</td></tr><tr><td>MYO9A</td><td>15q23</td><td>AR</td><td>post</td><td>con</td><td>&lt; 1</td></tr><tr><td>PLEC</td><td>8q24.3</td><td>AR</td><td>post</td><td>con</td><td>&lt; 1</td></tr><tr><td>PREP1</td><td>2p21</td><td>AR</td><td>post</td><td>con</td><td>&lt; 1</td></tr><tr><td>RAPSN</td><td>11p13-q1</td><td>AR</td><td>post</td><td>con, inf, child, adol, adult</td><td>10–20</td></tr><tr><td>SCN4A</td><td>17q23.3</td><td>AR</td><td>post</td><td>inf</td><td>&lt; 1</td></tr><tr><td>SLC18A3</td><td>10q11.23</td><td>AR</td><td>pre</td><td>con, inf</td><td>&lt; 1</td></tr><tr><td>SLC25A1</td><td>22q11.21</td><td>AR</td><td>post</td><td>inf</td><td>&lt; 1</td></tr><tr><td>SLC5A7</td><td>2q12.3</td><td>AD</td><td>pre</td><td>con, inf</td><td>&lt; 1</td></tr><tr><td>SNAP25</td><td>20p12.2</td><td>AD</td><td>pre</td><td>con</td><td>&lt; 1</td></tr><tr><td>SYB1</td><td>12p</td><td>uk</td><td>pre</td><td>inf</td><td>&lt; 1</td></tr><tr><td>SYT2</td><td>1q32.1</td><td>AD</td><td>pre</td><td>child</td><td>&lt; 1</td></tr><tr><td>VAMP1</td><td>12p13.21</td><td>AR</td><td>pre</td><td>con</td><td>&lt; 1</td></tr></tbody></table><table-wrap-foot><p><italic>MOI</italic> mode of inheritance, <italic>LD</italic> localisation of defect, pre: presynaptic, syn: synaptic, post: post-synaptic, glyc: glycosylation defect, <italic>OOCM</italic> onset of clinical manifestations, <italic>con</italic> congenital, <italic>inf</italic> infantile, <italic>child</italic> childhood, <italic>adol</italic> adolescence, adult: adulthood <italic>PCMS</italic> prevalence of various subtypes, <sup>a</sup>: according to [<xref ref-type="bibr" rid="CR6">6</xref>], <italic>uk</italic> unknown</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec6">
<title>Frequency</title>
<p id="Par39">Concerning the frequency of CMS only limited data are available since most of the current knowledge has been obtained by reports of isolated cases [<xref ref-type="bibr" rid="CR8">8</xref>]. According to a recent review, the prevalence of CMS is estimated as 1/10 that of myasthenia gravis, which is 25–125/1000000 [<xref ref-type="bibr" rid="CR6">6</xref>]. In a recent study on the frequency of autoimmune myasthenia and genetic myasthenia in patients under 18y of age, the prevalence of CMS in Great Britain was calculated as 9.2/1000000 but varies considerably between the regions between 2.8 and 14.8/1000000 [<xref ref-type="bibr" rid="CR9">9</xref>]. In the Brasilian state of Parana the prevalence of CMS was estimated as 0.18/100000 [<xref ref-type="bibr" rid="CR10">10</xref>]. Most likely, these prevalence figures are underestimations because CMS may go undetected if mixed up with one of the many differential diagnoses or if manifesting only with mild symptoms. In several regions worldwide local increases of certain mutations have been detected. In the Roma population of South-East Europe an increased frequency of the c.1327delG variant in the <italic>CHRNE</italic> gene has been reported [<xref ref-type="bibr" rid="CR11">11</xref>]. Similarly, an increased prevalence of the variant c.1353duplG in the <italic>CHRNE</italic> gene has been reported in Algeria and Tunisia [<xref ref-type="bibr" rid="CR12">12</xref>]. In Spain and Portugal the <italic>CHRNE</italic> variant c.130dupC is highly prevalent. <italic>CHRNE</italic>-related CMS is generally regarded as the most common of the CMS. In Western or central Europe the <italic>RAPSN</italic> variant c.264C &gt; A and the <italic>DOK7</italic> variant c.1124_1172dupTGCC are highly prevalent. Concerning the frequency of the 32 CMS subtypes, mutations in the <italic>CHRNE</italic> gene are the most frequent, accounting for 30–50% of the CMS cases, a figure which varies significantly between different ethnia [<xref ref-type="bibr" rid="CR13">13</xref>]. Mutations in the <italic>CHRNE</italic> gene result in acetylcholine-receptor deficiency or abnormal channel kinetics [<xref ref-type="bibr" rid="CR14">14</xref>]. The second most frequent defect is that in the <italic>RAPSN</italic> gene accounting for 15–20% of the CMS cases. The third and fourth most frequent CMS subtypes are <italic>COLQ</italic> and <italic>DOK7</italic> variants accounting for 10–15% of the CMS cases. Mutations in the <italic>CHAT</italic> gene account for 4–5% of the CMS cases [<xref ref-type="bibr" rid="CR6">6</xref>]. Mutations in <italic>GFPT1</italic> can be found in 2% of the CMS cases. However, these figures may vary between countries and regions under investigation. In a study of 34 CMS families from Israel the genes most frequently mutated were <italic>RAPSN</italic> (<italic>n</italic> = 13), <italic>COLQ</italic> (<italic>n</italic> = 11), and <italic>CHRNE</italic> (<italic>n</italic> = 7) [<xref ref-type="bibr" rid="CR15">15</xref>]. All other mutated proteins may contribute with less than 1% of the CMS cases to the general group of CMS. About 75% of the CMS cases are due to mutations in genes that encode different subunits of the acetylcholine receptor (<italic>CHRNA1, CHRNB1, CHRND, CHRNE</italic>) or proteins important to maintain the structure or function of the NMJ, such as <italic>MUSK</italic>, <italic>RAPSN</italic> or <italic>DOK7</italic> [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The most common causative genes are <italic>CHAT, COLQ, RAPSN, CHRNE, DOK7</italic>, and <italic>GFPT1</italic>.</p>
</sec>
<sec id="Sec7">
<title>Mutated proteins</title>
<p id="Par40">Currently, 32 proteins located on the presynaptic, synaptic or post-synaptic part of the motor endplate/neuromuscular junction (NMJ) or proteins undergoing abnormal glycosylation have been reported to be involved in the various types of CMS. Eight proteins are associated with presynaptic CMS, four with synaptic CMS, fifteen with post-synaptic CMS, and five with glycosylation defects. Proteins affected in CMS have different functions, such as ion channels (AchR, SNC4A), structural proteins (LAMA5, COL13A1, RAPSN, PLEC, COLQ), signalling molecules (AGRN, LRP4, MUSK, DOK7), catalytic enzymes (CHAT, GFPT1, DPAGT1, ALG14, ALG2, GMBBP, PREPL, SLC25A1), sensor proteins (SYT2), or transport proteins (SLC18A3) [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
<sec id="Sec8">
<title>Pre-synaptic CMS</title>
<p id="Par41">The majority of CMS is caused by defects in post-synaptic proteins but some of the CMSs are also caused by defects of the presynaptic proteins [<xref ref-type="bibr" rid="CR19">19</xref>]. These include the proteins SLC5A7, CHAT, SLC18A3, SNAP25, VAMP1, SYB1, SYT2, and MUNC13–1 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Presynaptic defects may be further categorised as disorders affecting the axonal transport, disorders affecting the synthesis and recycling of acetylcholine, and disorders affecting the exocytosis of synaptic vesicles.</p>
</sec>
<sec id="Sec9">
<title>Disorders affecting the axonal transport</title>
<sec id="FPar1">
<title>SLC5A7</title>
<p id="Par42">Recently, mutations in the presynaptic, Na-dependent, high-affinity choline transporter-1 (CHT) encoded by the <italic>SLC5A7</italic> gene have been identified as a rare cause of CMS [<xref ref-type="bibr" rid="CR20">20</xref>]. Mutations in this gene also cause allelic AD forms of distal motor neuropathy [<xref ref-type="bibr" rid="CR20">20</xref>]. Patients with <italic>SLC5A7</italic>-related CMS present with severe muscle weakness, ranging from lethal antenatal arthrogryposis and severe hypotonia to a neonatal form of CMS with episodic apneas. The prognosis of apneas is more favourable if patients respond to AchEI [<xref ref-type="bibr" rid="CR20">20</xref>]. In another family, patients presented with severe neuro-developmental delay with cerebral atrophy [<xref ref-type="bibr" rid="CR21">21</xref>]. Low-frequency repetitive nerve stimulation (LF-RNS) usually shows a decrement but sometimes only after previous high-frequency RNS (HF-RNS) during 10s with 20 Hz [<xref ref-type="bibr" rid="CR20">20</xref>]. All patients reported responded favourably to AchEI and one patient also to salbutamol [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
</sec>
</sec>
<sec id="Sec10">
<title>Disorders affecting the synthesis and recycling of acetylcholine</title>
<sec id="FPar2">
<title>Chat</title>
<p id="Par43">The <italic>CHAT</italic> gene encodes for the cholin acetyltransferase, which promotes the resynthesis of acetylcholine [<xref ref-type="bibr" rid="CR22">22</xref>]. Clinically, patients present with ptosis, limb muscle weakness, easy fatigability, and recurrent episodes of potentially fatal apnea [<xref ref-type="bibr" rid="CR22">22</xref>]. Episodes of apnea have an abrupt onset but may be triggered by physical or emotional stress or acute illness. Cerebral hypoxia/ischemia during apneic episodes may secondarily result in global developmental delay with delayed myelination and signs of hypoxic-ischemic injury on cerebral imaging [<xref ref-type="bibr" rid="CR23">23</xref>]. Apnea may be present already at birth or may rarely begin during childhood or early adulthood [<xref ref-type="bibr" rid="CR24">24</xref>]. Infections or stress may lead to life-threatening failure of neuromuscular transmission [<xref ref-type="bibr" rid="CR25">25</xref>]. Muscle MRI is usually normal [<xref ref-type="bibr" rid="CR26">26</xref>]. Ultrastructural investigations of the NMJ may be non-informative [<xref ref-type="bibr" rid="CR22">22</xref>]. In-vitro microelectrode studies performed in biopsied muscle may show moderate reduction of quantal release [<xref ref-type="bibr" rid="CR22">22</xref>]. AchEI may be beneficial for mild symptoms [<xref ref-type="bibr" rid="CR27">27</xref>] but may not prevent the occurrence of apneic episodes [<xref ref-type="bibr" rid="CR23">23</xref>]. Some patients may require permanent ventilation [<xref ref-type="bibr" rid="CR25">25</xref>]. Despite the application of AchEI, permanent proximal muscle weakness may develop and may lead to wheelchair-dependency [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
</sec>
<sec id="FPar3">
<title>SLC18A3</title>
<p id="Par44">The <italic>SLC18A3</italic> gene encodes the vesicular acetylcholine transporter VAchT [<xref ref-type="bibr" rid="CR19">19</xref>]. VAchT loads newly synthesised acetylcholine from the neuronal cytoplasm into synaptic vesicles [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. <italic>SLC18A3</italic>-related CMS have been reported in only three families [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Index cases from the first two families presented with ptosis, ophthalmoparesis, fatigue, weakness, and apneic crises [<xref ref-type="bibr" rid="CR29">29</xref>]. Interestingly, muscle manifestations in these patients deteriorated in cold water (paramyotonia) [<xref ref-type="bibr" rid="CR29">29</xref>]. One of the patients also had learning difficulties and left ventricular systolic dysfunction [<xref ref-type="bibr" rid="CR29">29</xref>]. The two patients from family 3 presented with respiratory failure since birth requiring mechanical ventilation [<xref ref-type="bibr" rid="CR19">19</xref>]. Index patients of family 1 and 3 showed prominent decrement on LF-RNS followed by a prolonged period of postactivation exhaustion [<xref ref-type="bibr" rid="CR29">29</xref>]. In one patient the decremental response could be unmasked only after isometric contraction, a well-recognised feature of presynaptic disease [<xref ref-type="bibr" rid="CR29">29</xref>]. AchEI were only moderately effective.</p>
</sec>
</sec>
<sec id="Sec11">
<title>Disorders affecting the exocytosis of synaptic vesicles</title>
<sec id="FPar4">
<title>SNAP25</title>
<p id="Par45"><italic>SNAP25</italic> encodes a “soluble <italic>N</italic>-ethyl-maleimide sensitive fusion (NSF) attachment” (SNARE) protein essential for exocytosis of synaptic vesicles from nerve terminals and of dense-core vesicles from endocrine cells [<xref ref-type="bibr" rid="CR30">30</xref>]. Ca++ − triggered exocytosis is initiated when synaptobrevin, attached to synaptic vesicles (v-SNARE), assembles with SNAP25B and syntaxin, anchored in the presynaptic membrane (t-SNAREs) into an α-helical coiled-coil, held together by hydrophobic interactions [<xref ref-type="bibr" rid="CR30">30</xref>]. Mutations in the <italic>SNAP25</italic> gene result in inhibition of synaptic vesicle exocytosis [<xref ref-type="bibr" rid="CR30">30</xref>]. <italic>SNAP25</italic>-related CMS has been reported only in a single female who presented with myasthenia, congenital contractures, cortical hyperexcitability, cerebellar ataxia, and severe intellectual disability [<xref ref-type="bibr" rid="CR30">30</xref>]. In this patient neuromuscular transmission was compromised due to reduced quantal release.</p>
</sec>
<sec id="FPar5">
<title>VAMP1</title>
<p id="Par46">The <italic>VAMP1</italic> gene encodes for a presynaptic protein, which is crucial for vesicle fusion at the presynaptic membrane [<xref ref-type="bibr" rid="CR31">31</xref>]. So far, <italic>VAMP1</italic>-related CMS has been reported in a Kuwaiti and an Israeli family [<xref ref-type="bibr" rid="CR31">31</xref>]. The two patients from the Kuwaiti family presented shortly after birth with hypotonia, muscle weakness, feeding difficulties requiring gavage feeding, delayed motor development, and ophthalmoparesis [<xref ref-type="bibr" rid="CR31">31</xref>]. One patient had joint contractures [<xref ref-type="bibr" rid="CR31">31</xref>]. The two patients from the Israeli family presented with severe congenital hypotonia and muscle weakness, feeding difficulties requiring percutaneous entero-gastrostomy (PEG) implantation, and severely delayed developmental milestones [<xref ref-type="bibr" rid="CR31">31</xref>]. One of them additionally had joint laxity and kyphoscoliosis, the other one had knee contractures and respiratory insufficiency [<xref ref-type="bibr" rid="CR31">31</xref>]. Both patients were unable to generate antigravity postures or movements [<xref ref-type="bibr" rid="CR31">31</xref>]. Electrophysiologic examination revealed severely low compound muscle action potentials (CMAPs) and presynaptic impairment [<xref ref-type="bibr" rid="CR31">31</xref>]. Both Israeli patients profited from pyridostigmine [<xref ref-type="bibr" rid="CR31">31</xref>].</p>
</sec>
<sec id="FPar6">
<title>SYB1</title>
<p id="Par47"><italic>SYB1</italic> encodes for the SNARE protein synaptobrevin, which is essential for synaptic vesicle exocytosis [<xref ref-type="bibr" rid="CR7">7</xref>]. Mutations in <italic>SYB1</italic> have been reported in a single patient with CMS [<xref ref-type="bibr" rid="CR7">7</xref>]. The female presented at birth with marked hypotonia and feeding difficulties [<xref ref-type="bibr" rid="CR7">7</xref>]. At age 2y, severe muscle weakness, wasting, and mild ophthalmoparesis developed [<xref ref-type="bibr" rid="CR7">7</xref>]. LF-RNS was followed by a decremental response, and 20 Hz stimulation during 5 s increased the CMAP-amplitude up to 9-fold [<xref ref-type="bibr" rid="CR7">7</xref>]. Pyridostigmine had a moderate beneficial effect [<xref ref-type="bibr" rid="CR7">7</xref>]. Over the years, muscle weakness slightly improved such that she could sit unaided but slurred speech and inability to swallow persisted [<xref ref-type="bibr" rid="CR7">7</xref>]. She died from respiratory failure precipitated by infection at age 14y [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
</sec>
<sec id="FPar7">
<title>SYT2</title>
<p id="Par48"><italic>SYT2</italic> encodes the presynaptic protein synaptotagmin that interacts with SNAP25 and is involved in the calcium-evoked acetylcholine release. <italic>SYT2</italic>-related CMS has been reported in two families [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Clinically, patients presented with prominent muscle weakness of the lower limbs and areflexia. Motor neuropathy has been another phenotypic feature. Various family members presented with foot deformities (pes cavus (hollow feet), hammertoes, pes planus, clawing), hyperlaxity, hip dysplasia, hypotonia, diffuse limb weakness and wasting, and mild ptosis [<xref ref-type="bibr" rid="CR32">32</xref>]. LF-RNS evoked a decremental response in several family members. Maximal voluntary contraction for 10s (facilitation) resulted in a marked increase of the CMAP [<xref ref-type="bibr" rid="CR32">32</xref>]. 3,4-DAP was more effective than pyridostigmine [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
</sec>
<sec id="FPar8">
<title>MUNC13–1</title>
<p id="Par49">MUNC13–1 acts as a master regulator of neurotransmitter release, mediating docking-priming of synaptic vesicles and various presynaptic plasticity processes [<xref ref-type="bibr" rid="CR34">34</xref>]. MUNC13–1 bridges the vesicle and plasma membranes from the periphery of the membrane-membrane interface [<xref ref-type="bibr" rid="CR34">34</xref>]. In the inactive state, MUNC13–1 locks syntaxin, another SNARE protein, in a folded state [<xref ref-type="bibr" rid="CR35">35</xref>]. Upon Ca2+ entry into the nerve terminal, MUNC13–1 unlocks syntaxin by displacing MUNC18 allowing syntaxin to interact with synaptobrevin and SNAP25B to effect vesicle exocytosis [<xref ref-type="bibr" rid="CR35">35</xref>]. Mutations in <italic>MUNC13–1</italic> have been reported only in a single patient. In a 2yo girl with generalised hypotonia, feeding difficulties, respiratory insufficiency, microcephaly, callosal atrophy, facial dysmorphism, variable ptosis, quadruparesis, scoliosis, flexion contractures, and paroxysmal EEG activity, whole exome sequencing (WES) revealed the homozygous mutation c.304C &gt; T in the <italic>MUNC13–1</italic> gene [<xref ref-type="bibr" rid="CR36">36</xref>]. The CMAP was low at rest, and LF-RNS revealed a decrement of 20–40% and HF-RNS an increment between 0.8 and 4 mV [<xref ref-type="bibr" rid="CR36">36</xref>]. Pyridostigmine and 3,4-DAP were only partially effective [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
</sec>
<sec id="FPar9">
<title>Synaptic CMS</title>
<p id="Par50">Four of the 32 subtypes of CMS are due mutations in genes encoding synaptic proteins. These include COLQ, LAMB2, LAMA5, and COL13A1 [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
</sec>
<sec id="FPar10">
<title>COLQ</title>
<p id="Par51"><italic>COLQ</italic> encodes a multidomain functional protein of the NMJ, crucial for anchoring AChE to the basal lamina and accumulating AChE at the NMJ [<xref ref-type="bibr" rid="CR37">37</xref>]. <italic>COLQ</italic>-related CMS may not only be due to point mutations, deletions or duplications, but also due to copy number variant mutations (deletion or duplication of the entire gene) [<xref ref-type="bibr" rid="CR21">21</xref>]. Mutations in <italic>COLQ</italic> cause AchE deficiency. Clinically, <italic>COLQ</italic>-related CMS presents with a broad range of features and severity from mild muscle manifestations, such as gait disturbance with independent ambulation and mild respiratory insufficiency, to wheel-chair boundness, or early death [<xref ref-type="bibr" rid="CR38">38</xref>]. Usually, however, the clinical manifestations are severe. Particularly the axial muscles can be severely affected and the ocular muscles are usually spared [<xref ref-type="bibr" rid="CR1">1</xref>]. Several patients with a limb-girdle muscular dystrophy (LGMD)-like phenotype have been reported [<xref ref-type="bibr" rid="CR39">39</xref>]. Some patients may experience short- or long-term relapses, being triggered by AchEI, infections, puberty, or pregnancy [<xref ref-type="bibr" rid="CR40">40</xref>]. Occasionally, the phenotype includes ptosis, ophthalmoparesis, or facial diplegia. The pupillary response may be slowed. Some patients may present with respiratory failure at birth or later in the course [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Some patients may present with severe scoliosis [<xref ref-type="bibr" rid="CR43">43</xref>]. In two patients, isolated vocal cord paralysis has been reported as initial manifestation, which did not respond to pyridostigmine, mildly to 3,4-DAP, but favourably to ephedrine [<xref ref-type="bibr" rid="CR42">42</xref>]. Rarely, microcephaly has been reported [<xref ref-type="bibr" rid="CR41">41</xref>]. Interestingly, heterozygote carriers can present with congenital ptosis [<xref ref-type="bibr" rid="CR44">44</xref>]. Single nerve stimuli may evoke double responses. Muscle MRI may be normal [<xref ref-type="bibr" rid="CR26">26</xref>]. Muscle biopsy may show mild fibre-size variation and marked type-I-muscle fiber predominance [<xref ref-type="bibr" rid="CR45">45</xref>]. Some patients may show dystrophic features and dystrophin deficiency [<xref ref-type="bibr" rid="CR45">45</xref>]. Biochemical investigations may reveal complex-I-deficiency [<xref ref-type="bibr" rid="CR45">45</xref>]. Pyridostigmine is ineffective or even detrimental [<xref ref-type="bibr" rid="CR46">46</xref>]. However, several patients have responded favourably to ephedrine [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] and some to salbutamol [<xref ref-type="bibr" rid="CR48">48</xref>].</p>
</sec>
<sec id="FPar11">
<title>LAMB2</title>
<p id="Par52">The <italic>LAMB2</italic> gene encodes for the laminin-beta-2 protein, which plays a major role in the development of the NMJ. The gene is ubiquitously expressed but manifests mainly at the NMJ. <italic>LAMB2</italic>-related CMS has been reported only in a single 22yo female so far [<xref ref-type="bibr" rid="CR49">49</xref>]. The patient presented clinically with episodes of respiratory distress, delayed motor milestones, and persistently constricted pupils and nephrotic syndrome (Pierson syndrome), requiring kidney transplantation [<xref ref-type="bibr" rid="CR49">49</xref>]. Later in the course, the patient developed ptosis, ophthalmoparesis, and scoliosis [<xref ref-type="bibr" rid="CR49">49</xref>]. LF-RNS was decremental, which became more pronounced at 10 Hz stimulation [<xref ref-type="bibr" rid="CR49">49</xref>]. Microelectrode recordings revealed profound reduction of the quantal content of endplate potentials [<xref ref-type="bibr" rid="CR49">49</xref>]. AchEI caused deterioration, such that the patient required ventilatory support [<xref ref-type="bibr" rid="CR49">49</xref>]. On the contrary, the patient responded favourably to ephedrine [<xref ref-type="bibr" rid="CR49">49</xref>].</p>
</sec>
<sec id="FPar12">
<title>LAMA5</title>
<p id="Par53">The <italic>LAMA5</italic> gene encodes for the protein laminin-A5 involved in the maintenance and function of the extracellular matrix [<xref ref-type="bibr" rid="CR50">50</xref>]. Laminin-A5 is a major component of the basal membrane and cooperates with growth factors and matrix-dependent receptors in cell proliferation and differentiation [<xref ref-type="bibr" rid="CR50">50</xref>]. <italic>LAMA5</italic>-related CMS has been reported only in a single patient [<xref ref-type="bibr" rid="CR51">51</xref>]. The female presented at age 24y with muscle weakness, myopia, and facial tics [<xref ref-type="bibr" rid="CR51">51</xref>]. Cerebral MRI showed mild volume loss and periventricular T2-hyperintensities [<xref ref-type="bibr" rid="CR51">51</xref>]. LF-RNS evoked a decrement of 55% but a 250% increment after 10s of maximal contraction [<xref ref-type="bibr" rid="CR51">51</xref>]. Endplate studies identified profound reduction of the endplate potential quantal content and endplates with normal post-synaptic folding that were denervated or innervated by small nerve terminals [<xref ref-type="bibr" rid="CR51">51</xref>].</p>
</sec>
<sec id="FPar13">
<title>COL13A1</title>
<p id="Par54">The <italic>COL13A1</italic> gene encodes the α-chain of an atypical non-fibrillar collagen with a single transmembrane domain [<xref ref-type="bibr" rid="CR52">52</xref>]. COL13A1 is localised to the NMJ, where it is responsible for clustering of the AchR during myotube differentiation [<xref ref-type="bibr" rid="CR52">52</xref>]. Mutations in this gene manifest clinically as CMS, which has been reported in three patients (2 females, 1 male) from two families [<xref ref-type="bibr" rid="CR52">52</xref>]. Two of these patients manifested with congenital respiratory insufficiency, bulbar weakness, or facial weakness. All three patients presented with feeding difficulties, ptosis, limb weakness, and dysmorphism [<xref ref-type="bibr" rid="CR52">52</xref>]. Two patients each presented with spinal stiffness or distal joint laxity, and one patient with ophthalmoparesis and cognitive impairment. Two showed a decremental response to RNS and two an increased jitter [<xref ref-type="bibr" rid="CR52">52</xref>]. Two required non-invasive positive pressure ventilation (NIPPV). In two patients pyridostigmine was ineffective. Salbutamol respectively 3,4-DAP was beneficial [<xref ref-type="bibr" rid="CR52">52</xref>].</p>
</sec>
</sec>
<sec id="Sec12">
<title>Post-synaptic disorders</title>
<p id="Par55">Fifteen of the CMS subtypes are due to mutations in genes encoding post-synaptic proteins. These include CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, DOK7, MUSK, MYO9A, AGRN, LRP4, PREP1, SCN4A, RAPSN, PLEC, and SLC25A1. Thus, post-.synaptic CMSs represent the vast majority of the CMS subtypes. Post-synaptic CMS are subdivided into primary AchR deficiency, kinetic abnormalities of the AChR, and defects within the AchR-clustering pathway.</p>
</sec>
<sec id="Sec13">
<title>Primary AchR deficiency</title>
<sec id="FPar14">
<title>CHRNA1</title>
<p id="Par56">The <italic>CHRNA1</italic> gene encodes the α-subunit of the nicotinergic, post-synaptic AchR. <italic>CHRNA1</italic> mRNA undergoes alternative splicing and two splice variants (P3A- and P3A+) are produced [<xref ref-type="bibr" rid="CR53">53</xref>]. Mutations in <italic>CHRNA1</italic> result in imbalance between the two splice variants with an increase in P3A+. <italic>CHRNA1</italic> mutations reduce the number of AchR at the post-synaptic membrane [<xref ref-type="bibr" rid="CR54">54</xref>]. The pattern of inheritance is AD if <italic>CHRNA1</italic> mutations cause a slow channel CMS (SCCMS) or AR in case of primary AchR-deficiency [<xref ref-type="bibr" rid="CR54">54</xref>]. The first <italic>CHRNA1</italic>-related CMS were reported in 2008 [<xref ref-type="bibr" rid="CR54">54</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>). Patients presented already prenatally with growth retardation, reduced movements, edema, contractures, and postnatally with dysmorphism, muscle wasting, scoliosis, contractures, and pterygia [<xref ref-type="bibr" rid="CR55">55</xref>]. Concerning the frequency of <italic>CHRNA1</italic> mutations, they were found only in a single of 18 Brasilian families with CMS [<xref ref-type="bibr" rid="CR10">10</xref>]. <italic>CHRNA1</italic>-related CMS seems to respond favourably to AchEI [<xref ref-type="bibr" rid="CR54">54</xref>]. Antisense oligonucleotides (AONs) have been shown to restore the balance between the two splice variants and are thus expected to be beneficial in patients carrying such mutations [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
</sec>
<sec id="FPar15">
<title>CHRNB1</title>
<p id="Par57">The <italic>CHRNB1</italic> gene encodes for the β-subunit of the nicotinergic, post-synaptic AchR. The first mutations in <italic>CHRNB1</italic> causing CMS were reported in a Brazilian study in 2008 [<xref ref-type="bibr" rid="CR10">10</xref>] (Table <xref ref-type="table" rid="Tab1">1</xref>). The first patient published was a 28yo male manifesting since birth with ptosis, ophthalmoparesis, dysphagia, proximal limb muscle weakness, scapular winging, weakness of axial muscles, wasting, and scoliosis [<xref ref-type="bibr" rid="CR10">10</xref>]. He showed a decremental response to RNS, had double discharges, and a myopathic EMG. The course was progressive but he benefitted from fluoxetine [<xref ref-type="bibr" rid="CR10">10</xref>]. The second patient carrying a <italic>CHRNB1</italic> mutation was a 3wo male manifesting with ptosis, facial weakness, severe hypotonia, and respiratory insufficiency requiring assisted ventilation [<xref ref-type="bibr" rid="CR56">56</xref>]. The response to LF-RNS was decremental. AchEI were ineffective and he was put on quinidine but was lost to follow-up [<xref ref-type="bibr" rid="CR56">56</xref>]. In a Spanish study of a CMS cohort, a third patient with a <italic>CHRNB1</italic> mutation was identified but no clinical details were provided [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
</sec>
<sec id="FPar16">
<title>CHRND</title>
<p id="Par58">The <italic>CHRND</italic> gene encodes the δ-subunit of the nicotinergic, post-synaptic AchR. The first mutation in <italic>CHRND</italic> causing CMS was reported in a German patient with early-onset CMS manifesting with feeding difficulties, moderate, generalised weakness, and recurrent episodes of respiratory insufficiency provoked by infections [<xref ref-type="bibr" rid="CR58">58</xref>]. The second patient was a 20yo female with moderate to severe myasthenic manifestations since birth [<xref ref-type="bibr" rid="CR59">59</xref>]. She had a marked decremental response to LF-RNS. She responded poorly to AchEI but clearly to 3,4-DAP [<xref ref-type="bibr" rid="CR59">59</xref>]. One of her siblings with a similar presentation had died at age 11 m [<xref ref-type="bibr" rid="CR59">59</xref>]. Two further patients were reported in a study of CMS patients from Israel but no clinical details were provided [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
</sec>
<sec id="FPar17">
<title>CHRNE</title>
<p id="Par59">The <italic>CHRNE</italic> gene encodes for the ε-subunit of the AchR. The first mutation in the <italic>CHRNE</italic> gene causing a CMS has been reported already in 2000 (Table <xref ref-type="table" rid="Tab1">1</xref>) [<xref ref-type="bibr" rid="CR60">60</xref>]. Since then various different types of mutations have been reported and it is estimated that up to half of the patients with a CMS carry a <italic>CHRNE</italic> mutation, thus representing the gene most frequently mutated in CMS [<xref ref-type="bibr" rid="CR6">6</xref>]. In a study of 64 CMS patients from Spain, <italic>CHRNE</italic> mutations were detected in 27% of the patients [<xref ref-type="bibr" rid="CR57">57</xref>]. In a study of 45 patients from 35 Israeli CMS families, <italic>CHRNE</italic> mutations were found in 7 kinships [<xref ref-type="bibr" rid="CR15">15</xref>]. In a study of 23 families with CMS from Maghreb countries, the founder mutation c.1293insG was found in 60% of these patients [<xref ref-type="bibr" rid="CR61">61</xref>]. Type and severity of clinical manifestations of <italic>CHRNE</italic> mutations may vary considerably between affected families. Some patients may present with only ptosis whereas others may present with severe generalised myasthenia [<xref ref-type="bibr" rid="CR62">62</xref>]. Most patients present at birth with mildly progressive bulbar, respiratory, or generalized limb weakness with ptosis or ophthalmoplegia [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Single patients may die prematurely in infancy from respiratory failure [<xref ref-type="bibr" rid="CR65">65</xref>]. Some patients may have myasthenic symptoms since birth and achieve ambulation late or not at all [<xref ref-type="bibr" rid="CR65">65</xref>]. Single patients present with a fluctuating course [<xref ref-type="bibr" rid="CR57">57</xref>]. Single patients develop severe scoliosis [<xref ref-type="bibr" rid="CR27">27</xref>]. RNS may be decremental [<xref ref-type="bibr" rid="CR27">27</xref>] or may be normal [<xref ref-type="bibr" rid="CR64">64</xref>]. Single-fiber EMG (SF-EMG) may reveal an increased jitter [<xref ref-type="bibr" rid="CR64">64</xref>]. Some patients may show repetitive CMAPs [<xref ref-type="bibr" rid="CR27">27</xref>]. Most patients respond favourably to AchEI [<xref ref-type="bibr" rid="CR61">61</xref>]. However, in some patients pyridostigmine and 3,4-DAP may be ineffective or may worsen the phenotype. Albuterol can be highly effective in single patients [<xref ref-type="bibr" rid="CR66">66</xref>]. Other patients may profit significantly from salbutamol [<xref ref-type="bibr" rid="CR14">14</xref>]. Fluoxetine alone may be ineffective but in combination with salbutamol a significant improvement can be achieved [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
</sec>
<sec id="FPar18">
<title>CHRNG</title>
<p id="Par60">The <italic>CHRNG</italic> gene encodes for the fetal γ-subunit of the AchR. Mutations in the <italic>CHRNG</italic> gene cause CMS with multiple ptyerygia (lethal multiple pterygia syndrome (LMPS) or the Escobar variant of multiple pterygia syndrome (EVMPS)) [<xref ref-type="bibr" rid="CR68">68</xref>]. In a study of seven families with Escobar syndrome (contractions, multiple pterygia, respiratory distress), mutations in the <italic>CHRNG</italic> gene were detected in 12 family members [<xref ref-type="bibr" rid="CR68">68</xref>]. The female to male ratio was 7:5. Some patients presented with decreased fetal movements, facial weakness, respiratory distress, arthrogryposis, short stature, kyphosis/scoliosis, dysmorphism, high-arched palate, cleft palate, arachnodactyly, or cryptorchism [<xref ref-type="bibr" rid="CR68">68</xref>]. None presented with myasthenic manifestations postnatally. <italic>CHRNG</italic> mutations may be also responsible for the allelic disease fetal akinesia deformation sequence (FADS) [<xref ref-type="bibr" rid="CR54">54</xref>]. In a study of 46 CMS patients from Spain, five carried a mutation in the <italic>CHRNG</italic> gene [<xref ref-type="bibr" rid="CR57">57</xref>]. They all presented with arthrogryposis and delayed motor milestones, and some of them with poor sucking [<xref ref-type="bibr" rid="CR57">57</xref>]. Interestingly, none of them received drugs usually given for CMS. In a study of three Iranian <italic>CHRNG</italic>-related CMS patients, no drug treatment was applied [<xref ref-type="bibr" rid="CR69">69</xref>]. One of the patients presented with short neck, mild axillar pterygia, elbows and knees, joint contractures, clenched hands with thumbs held across palm and club feet (varus). The patient had rockerbottom feet, with almost no movement in ankles. Facial dysmorphism included hemangioma over forehead and nose, strabismus, flat nasal bridge, and downturned corners of mouth [<xref ref-type="bibr" rid="CR69">69</xref>].</p>
</sec>
</sec>
<sec id="Sec14">
<title>Kinetic abnormalities of the AChR</title>
<p id="Par61">According to the kinetics of the AChR, two functionally distinct types of CMS are differentiated, fast channel CMS (FCCMS) and SCCMS.</p>
<sec id="FPar19">
<title>FCCMS</title>
<p id="Par62">FCCMS is characterized by only a short opening time of the AchR. FCCNS is due to loss of function mutations in subunits of the AchR. These mutations cause abnormally brief AChR channel openings by enhancing the channel closing rate or by curtailing the channel opening rate. [<xref ref-type="bibr" rid="CR35">35</xref>]. Decrease in AChR affinity for acetylcholine or altered fidelity of channel openings can also cause shortened channel openings [<xref ref-type="bibr" rid="CR35">35</xref>]. The safety margin of neuromuscular transmission is compromised by the decreased probability of channel openings and by the accelerated decay of the synaptic response [<xref ref-type="bibr" rid="CR35">35</xref>]. FCCMS usually present in early childhood with an infantile phenotype. FCCMS responds to 3,4-DAP in combination with pyridostigmine [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
</sec>
<sec id="FPar20">
<title>SCCMS</title>
<p id="Par63">SCCMS, on the contrary, is characterized by a prolonged opening time of the AchR. SCCMS are usually due to gain-of-function mutations in AchR subunit genes. In most patients, SCCMS follows an AD trait of inheritance [<xref ref-type="bibr" rid="CR1">1</xref>]. On the contrary, most primary AchR deficiency syndromes follow an AR trait of inheritance. Mutations in any of the four AChR adult subunits can alter ion channel function of the AchR. Onset of SCCMS subtypes is usually after adolescence with initially mild phenotypes. Only rare cases present in early life and become severely disabled in the first decade [<xref ref-type="bibr" rid="CR18">18</xref>]. In most patients there is selective, severe involvement of cervical and wrist and finger extensor muscles [<xref ref-type="bibr" rid="CR35">35</xref>]. Electrophysiological investigations of SCCMS frequently reveal repetitive discharges (a single nerve stimulus evokes repetitive compound muscle action potentials) [<xref ref-type="bibr" rid="CR1">1</xref>]. Intake of AchEI typically deteriorates the clinical manifestations [<xref ref-type="bibr" rid="CR1">1</xref>]. SCCMS do not respond to edrophonium.</p>
</sec>
</sec>
<sec id="Sec15">
<title>Defects within the AchR-clustering pathway</title>
<sec id="FPar21">
<title>DOK7</title>
<p id="Par64">The <italic>DOK7</italic> (downstream-of-kinase) gene encodes for the protein DOK7, which is involved in signaling downstream of receptor and non-receptor phosphotyrosine kinases [<xref ref-type="bibr" rid="CR70">70</xref>]. DOK7 activates MUSK via dimerisation [<xref ref-type="bibr" rid="CR71">71</xref>]. Various mutations have been reported in the <italic>DOK7</italic> gene. Particularly reported were deletions [<xref ref-type="bibr" rid="CR72">72</xref>]. They may occur during DNA replication since there is breakpoint microhomology and an inverted repeat [<xref ref-type="bibr" rid="CR72">72</xref>]. Concerning the frequency of <italic>DOK7</italic>-related CMS, it was the second most frequent subtype in a Brasilian cohort [<xref ref-type="bibr" rid="CR10">10</xref>]. Clinical onset is characterised by gait disturbance due to muscle weakness after normal motor milestones [<xref ref-type="bibr" rid="CR73">73</xref>]. Proximal limb muscles are more strongly affected than distal limb muscles (LGMD-like pattern) [<xref ref-type="bibr" rid="CR73">73</xref>]. Congenital <italic>DOK7</italic>-related CMS may manifest as stridor due to vocal cord paralysis, occasionally requiring intubation and artificial ventilation [<xref ref-type="bibr" rid="CR74">74</xref>]. Occasionally, patients present with ptosis but only rarely with ophthalmoparesis. Fatigability is often absent but prolonged periods of weakness may occur [<xref ref-type="bibr" rid="CR75">75</xref>]. Feeding difficulties may require nasogastral tube feeding or even PEG implantation [<xref ref-type="bibr" rid="CR74">74</xref>]. Muscle biopsy may show lipidosis and defective branching of terminal axons, which results in a unique terminal axon contacting en passant post-synaptic cups [<xref ref-type="bibr" rid="CR76">76</xref>]. AchEI are usually ineffective and may even worsen clinical manifestations [<xref ref-type="bibr" rid="CR73">73</xref>]. Ephedrine (initially 25 mg/d and increased to 75-100 mg/d) seems to be an effective alternative [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Salbutamol may be effective in <italic>DOK7</italic>-related CMS as well [<xref ref-type="bibr" rid="CR79">79</xref>]. Single patients profit from albuterol, which can prevent progression of muscle weakness in LGMD-type <italic>DOK7</italic>-related CMS [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
</sec>
<sec id="FPar22">
<title>Musk</title>
<p id="Par65"><italic>MUSK</italic> encodes for a protein that is involved in endplate maturation, maintenance of the endplate functions, proper functioning of rapsyn, and functioning of the AchR [<xref ref-type="bibr" rid="CR24">24</xref>]. MUSK forms a co-receptor for agrin with LRP4 and induces AchR clustering [<xref ref-type="bibr" rid="CR18">18</xref>]. CMS due to <italic>MUSK</italic> mutations is rare and manifests as respiratory insufficiency, neonatal ptosis, proximal limb muscle weakness, and weak bulbar, facial, or ocular muscles [<xref ref-type="bibr" rid="CR18">18</xref>]. A 30yo Chinese male with the LGMD-type of <italic>MUSK</italic>-related CMS developed mild atrophy of the leg muscles [<xref ref-type="bibr" rid="CR81">81</xref>]. LF-RNS was decremental. Pyridostigmin deteriorated the clinical manifestations [<xref ref-type="bibr" rid="CR81">81</xref>]. Another male infant manifested with congenital respiratory failure requiring mechanical ventilation, axial weakness with head drop, facial weakness, proximal limb weakness, and ophthalmoparesis [<xref ref-type="bibr" rid="CR82">82</xref>]. Salbutamol was effective but 3,4-DAP had only a mild effect, and AchEI worsened the phenotype [<xref ref-type="bibr" rid="CR82">82</xref>]. In a female with congenital hypotonia and respiratory distress requiring mechanical ventilation for 8 m, respiratory distress and nocturnal apnea with vocal cord paralysis recurred at age 8y [<xref ref-type="bibr" rid="CR42">42</xref>]. 3,4-DAP was effective [<xref ref-type="bibr" rid="CR42">42</xref>]. In two Turkish brothers <italic>MUSK</italic> mutations manifested as LGMD-type CMS [<xref ref-type="bibr" rid="CR83">83</xref>]. <italic>MUSK</italic>-related CMS may also manifest as congenital ptosis and later in life with fatigability [<xref ref-type="bibr" rid="CR84">84</xref>]. In another patient with <italic>MUSK</italic>-related CMS and congenital respiratory insufficiency, albuterol was moderately effective but AchEI, 3,4-DAP, and ephedrine were ineffective [<xref ref-type="bibr" rid="CR85">85</xref>].</p>
</sec>
<sec id="FPar23">
<title>MYO9A</title>
<p id="Par66">The <italic>MYO9A</italic> gene encodes an unconventional myosin [<xref ref-type="bibr" rid="CR86">86</xref>]. Mutations in the <italic>MYO9A</italic> gene causing CMS have been reported in 3 patients from 2 unrelated families [<xref ref-type="bibr" rid="CR86">86</xref>]. Patient-1 presented as a neonate with dysphagia requiring PEG-feeding, limb muscle weakness, episodic apnoea, respiratory failure, and ptosis. SF-EMG showed an increased jitter in the orbicularis oculi muscle. The patient responded favourably to a combination of pyridostigmine and 3,4-DAP [<xref ref-type="bibr" rid="CR86">86</xref>]. Patients-2 and 3 were two Kurdish siblings, both with prenatal onset with reduced fetal movements. At birth patient-2 presented with bilateral ptosis and after 2 months with generalized hypotonia and dysphagia and chewing difficulty. She had delayed motor milestones, symmetric, multivectorial nystagmus, left eye upgaze deviation, and ophthalmoplegia. Respiratory crises could be triggered by 3.4-DAP, fluoxetine, and respiratory infections. Patient-3 presented with bilateral ptosis within the first week after birth, ophthalmoplegia, nystagmus, and oculomotor apraxia, and developed generalized hypotonia, absence of head and truncal control, and difficulty with swallowing and chewing. Sitting was achieved at 12 m, head control at 18 m, and the ability to walk unassisted at 30 m of age. RNS was decremental. Both patients responded favourably to pyridostigmine. The unaffected parents were consanguineous and had previously lost four children during the first year of life, all with respiratory failure, feeding difficulties, and hypotonia [<xref ref-type="bibr" rid="CR86">86</xref>].</p>
</sec>
<sec id="FPar24">
<title>AGRN</title>
<p id="Par67">The <italic>AGRN</italic> gene encodes for a proteoglycan, which is secreted by the terminal nerve into the synaptic cleft. At the post-synaptic membrane agrin binds to the LRP4 receptor to phosphorylate and activate MUSK [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, agrin plays a critical role in the development and maintenance of the NMJ [<xref ref-type="bibr" rid="CR87">87</xref>]. Mutations in the <italic>AGRN</italic> gene manifest phenotypically as either early-onset or late-onset CMS [<xref ref-type="bibr" rid="CR24">24</xref>]. The infantile-onset type is characterised by weakness and wasting of the lower limbs with fatty replacement of myocytes in the posterior compartment. The late-onset type is characterised by ptosis, ophthalmoparesis, and mild facial and bulbar weakness. Rarely, mutations in the <italic>AGRN</italic> gene may be associated with dropped head syndrome [<xref ref-type="bibr" rid="CR87">87</xref>]. In a study of 5 patients from 3 families carrying <italic>AGRN</italic> mutations, all presented with permanent distal muscle weakness and wasting in addition to myasthenia [<xref ref-type="bibr" rid="CR88">88</xref>]. Both types of <italic>AGRN</italic>-related CMS respond favourably to ephedrine. Pyridostigmine and amifampridine were ineffective [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
</sec>
<sec id="FPar25">
<title>LRP4</title>
<p id="Par68">The <italic>LRP4</italic> gene encodes for a protein, which functions as a receptor for agrin [<xref ref-type="bibr" rid="CR89">89</xref>]. LRP4 forms a complex with MUSK and mediates MUSK activation by agrin [<xref ref-type="bibr" rid="CR89">89</xref>]. Activated MUSK together with DOK7 stimulates rapsyn to concentrate and anchor AchR at the post-synaptic membrane and interacts with other proteins implicated in the assembly and maintenance of the NMJ [<xref ref-type="bibr" rid="CR90">90</xref>]. LRP4 is thus essential for pre- and post-synaptic specialisation of the NMJ [<xref ref-type="bibr" rid="CR91">91</xref>]. The first mutation in the <italic>LRP4</italic> gene causing CMS was reported in 2014 (Table <xref ref-type="table" rid="Tab1">1</xref>) [<xref ref-type="bibr" rid="CR90">90</xref>]. A newborn female presented with respiratory arrest and feeding difficulties, and required feeding and ventilator support until 6 m of age [<xref ref-type="bibr" rid="CR90">90</xref>]. Motor milestones were delayed and she developed easy fatigability with temporary wheelchair-dependency [<xref ref-type="bibr" rid="CR90">90</xref>]. At ages 9 and 14y she presented with ptosis, ophthalmoparesis, and limb weakness [<xref ref-type="bibr" rid="CR90">90</xref>]. RNS evoked a decremental response, which improved upon application of edrophonium. AchEI worsened the clinical manifestations [<xref ref-type="bibr" rid="CR90">90</xref>]. A second kinship harbouring <italic>LRP4</italic> mutations was reported in 2015 [<xref ref-type="bibr" rid="CR92">92</xref>]. The two sisters, aged 34 and 20y, presented with delayed motor milestones, slight chewing and swallowing difficulties, and later developed limb weakness [<xref ref-type="bibr" rid="CR92">92</xref>]. Albuterol was highly effective [<xref ref-type="bibr" rid="CR92">92</xref>].</p>
</sec>
<sec id="FPar26">
<title>PREPL</title>
<p id="Par69"><italic>PREPL</italic> encodes for an ubiquitously occurring propyl-endopeptidase, with highest levels in the brain, kidneys, and muscle [<xref ref-type="bibr" rid="CR93">93</xref>]. PREPL acts as an effector of the clathrin-associated adaptor protein-1 (AP-1) by binding to its m1A subunit to release AP-1 from target membranes [<xref ref-type="bibr" rid="CR93">93</xref>]. Since trafficking of the vesicular acetylcholine transporter between the synaptic vesicle membrane and the cytosol depends on AP-1, absence of PREPL could explain the reduced filling of synaptic vesicles with acetylcholine [<xref ref-type="bibr" rid="CR93">93</xref>]. Mutations in the <italic>PREPL</italic> gene cause isolated PREPL deficiency [<xref ref-type="bibr" rid="CR93">93</xref>]. So far, only a single patient with isolated PREPL-deficiency has been reported [<xref ref-type="bibr" rid="CR93">93</xref>]. The female presented with congenital hypotonia, feeding difficulties, ptosis, and proximal muscle weakness. She later developed a waddling gait and used a walker [<xref ref-type="bibr" rid="CR93">93</xref>]. LF-RNS did not evoke a decrement. The patient responded favorably to edrophonium and pyridostigmine.</p>
</sec>
<sec id="FPar27">
<title>SCN4A</title>
<p id="Par70"><italic>SCN4A</italic> encodes for a post-synaptic sodium channel responsible for the generation of membrane action potentials. Phenotypically, mutations in this gene manifest in infancy with global hypotonia, impaired sucking, dysphagia, delayed postural and motor development and later in life with episodic, fluctuating muscle weakness like in periodic paralysis, bilateral facial palsy, ptosis, and ophthalmoparesis [<xref ref-type="bibr" rid="CR94">94</xref>]. Episodes of periodic weakness could not be triggered by exercise, rest, potassium loading, or food, like in periodic paralysis [<xref ref-type="bibr" rid="CR94">94</xref>]. In older patients, <italic>SCN4A</italic>-related CMS may manifest exclusively as easy fatigability [<xref ref-type="bibr" rid="CR95">95</xref>]. In a 20yo normokalemic female, <italic>SCN4A</italic>-related CMS manifested as sudden attacks of respiratory and bulbar paralysis since birth, lasting 3–30 min and recurring one to three times per month, delayed motor development, easy fatigability, ptosis, ophthalmoparesis, and later as persisting facial, truncal, or limb weakness [<xref ref-type="bibr" rid="CR96">96</xref>]. Some patients present with dysmorphism, such as high-arched palate, adduction deformity of the knees or ankles, and increased lumbar lordosis. Some patients are mentally retarded with cerebral atrophy on MRI [<xref ref-type="bibr" rid="CR96">96</xref>]. RNS may be normal but higher stimulus frequency may trigger a decremental response [<xref ref-type="bibr" rid="CR94">94</xref>]. AchEI are only marginally effective [<xref ref-type="bibr" rid="CR94">94</xref>]. Acetazolamide together with potassium was ineffective [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
</sec>
<sec id="FPar28">
<title>RAPSN</title>
<p id="Par71"><italic>RAPSN</italic> encodes for rapsyn, a post-synaptic membrane protein that anchors the nicotinic AchR to the motor endplate and also binds to β-dystroglycan [<xref ref-type="bibr" rid="CR18">18</xref>]. Rapsyn is essential for clustering of the AchR at the post-synaptic membrane and required for the phosphorylation of CHRNB1 [<xref ref-type="bibr" rid="CR18">18</xref>]. <italic>RAPSN</italic> mutations are a common cause of post-synaptic CMS [<xref ref-type="bibr" rid="CR97">97</xref>]. The most common of the <italic>RAPSN</italic> mutation is N88G, but hetero-allelic mutations other than N88K can also occur [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Occasionally, mutations in <italic>RAPSN</italic> become pathogenic only in case mutations in the <italic>AK9</italic> gene are simultaneously present [<xref ref-type="bibr" rid="CR100">100</xref>]. Clinically, patients present with fluctuating ptosis, occasionally bulbar symptoms, neck muscle and mild proximal limb muscle weakness [<xref ref-type="bibr" rid="CR97">97</xref>]. Infections can precipitate exacerbation of clinical manifestations [<xref ref-type="bibr" rid="CR97">97</xref>]. In single patients prominent hyperlordosis can occur [<xref ref-type="bibr" rid="CR101">101</xref>]. Usually, the response to AchEI is favourable but can be improved by adding 3,4 DAP [<xref ref-type="bibr" rid="CR97">97</xref>]. Fluoxetine may worsen the decremental response in single patients [<xref ref-type="bibr" rid="CR102">102</xref>]. In some patients general anesthesia may exacerbate muscle weakness [<xref ref-type="bibr" rid="CR103">103</xref>]. The overall course is stable with intermittent worsenings [<xref ref-type="bibr" rid="CR97">97</xref>].</p>
</sec>
<sec id="FPar29">
<title>PLEC1</title>
<p id="Par72"><italic>PLEC1</italic> encodes for plectin, which crosslinks intermediate filaments to their targets in different tissues. The gene is ubiquitously expressed but manifests mainly in the skin, gastrointestinal tract, and the NMJ. The first patient with CMS due to a <italic>PLEC1</italic> mutation had early-onset muscular dystrophy and late-onset manifestations of a myasthenic syndrome (Table <xref ref-type="table" rid="Tab1">1</xref>) [<xref ref-type="bibr" rid="CR104">104</xref>]. RNS evoked a prominent decremental response [<xref ref-type="bibr" rid="CR104">104</xref>]. AchEI (pyridostigmine) resulted in marked improvement of the muscular manifestations [<xref ref-type="bibr" rid="CR104">104</xref>]. A second patient with epidermiolysis bullosa and CMS carried not only a <italic>PLEC1</italic> mutation but also a homozygous <italic>CHRNE</italic> mutation why it was difficult to decide to which degree the <italic>PLEC1</italic> mutation contributed to the CMS phenotype [<xref ref-type="bibr" rid="CR105">105</xref>]. A third, Afro-American patient with epidermiolysis bullosa (EDB) developed myasthenic symptoms at age 39y [<xref ref-type="bibr" rid="CR106">106</xref>]. RNS induced a decremental response already at age 15y. Histologically, NMJs showed destruction of the junctional folds and remodelling [<xref ref-type="bibr" rid="CR106">106</xref>]. The patient died motionless at age 42y [<xref ref-type="bibr" rid="CR106">106</xref>].</p>
</sec>
<sec id="FPar30">
<title>SLC25A1</title>
<p id="Par73"><italic>SLC25A1</italic> encodes the mitochondrial citrate carrier across the inner mitochondrial membrane and is believed to be a key player in fatty acid and sterol biosynthesis, in chromosome integrity, and in autophagy regulation [<xref ref-type="bibr" rid="CR107">107</xref>]. Missense mutations in the <italic>SLC25A1</italic> gene result in abnormal carrier function [<xref ref-type="bibr" rid="CR107">107</xref>], hydroxyl-glutaric aciduria, and CMS. So far, CMS due to <italic>SLC25A1</italic> mutations has been reported in 3 English sibs. Two of them presented with easy fatigability and permanent weakness since early infancy [<xref ref-type="bibr" rid="CR107">107</xref>]. One had had moderate intellectual disability [<xref ref-type="bibr" rid="CR107">107</xref>]. Another developed obsessive convulsive tendencies and had pes cavus [<xref ref-type="bibr" rid="CR107">107</xref>]. The third patient had a more severe phenotype with poor suck, hypotonia, apneas, optic atrophy, psychomotor delay, bulbar dysfunction, epilepsy, agenesis of the corpus callosum, hearing loss, and elevated urinary organic acids [<xref ref-type="bibr" rid="CR107">107</xref>]. RNS was normal but SF-EMG revealed an increased jitter [<xref ref-type="bibr" rid="CR107">107</xref>]. Only one of the three patients responded favourably to 3,4-DAP [<xref ref-type="bibr" rid="CR107">107</xref>]. Pyridostigmine was ineffective in one case.</p>
</sec>
</sec>
<sec id="Sec16">
<title>Glycosylation disorders</title>
<p id="Par74">CMS may not only be due to mutations in genes involved in the structure and function of the motor endplate but also in genes involved in the glycosylation of proteins, lipids, or aglykones. Particularly glycosylation of AchR is impaired in CMS due to defective glycosylation. Glycosilation is essential for proper functioning of the NMJ and takes place in the endoplasmatic reticulum (ER) [<xref ref-type="bibr" rid="CR108">108</xref>]. Currently, mutations in five genes are known that are involved in protein glycosylation and may be associated with CMS. These genes include <italic>ALG2, ALG14, DPAGT1, GFPT1</italic>, and <italic>GMPPB</italic> [<xref ref-type="bibr" rid="CR109">109</xref>]. Though they are ubiquitously expressed, they predominantly manifest at the NMJ. Because of the clinical and histological findings the term “limb-girdle myasthenic syndrome with tubular aggregates” was coined.</p>
<sec id="FPar31">
<title>GFPT1</title>
<p id="Par75"><italic>GFPT1</italic> encodes for the glutamine-fructose-6-phosphate transaminase-1, which is a key rate-limiting enzyme that controls the flux of glucose into the hexosamine biosynthetic pathway, providing building blocks for the glycosylation of proteins and lipids [<xref ref-type="bibr" rid="CR110">110</xref>]. <italic>GFPT1</italic> is ubiquitously expressed but it is not readily apparent why mutations in this gene cause symptoms restricted to the NMJ [<xref ref-type="bibr" rid="CR110">110</xref>]. Mutations in <italic>GFPT1</italic> may lead to illegitimate binding of micro-RNAs resulting in reduced protein expression [<xref ref-type="bibr" rid="CR111">111</xref>]. Patients manifest clinically with early-onset prominent LGMD-like weakness, easy fatigability and minimal cranio-bulbar symptoms [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. Muscle MRI may reveal T1-hyperintensities [<xref ref-type="bibr" rid="CR26">26</xref>]. Maintenance of NMJs is dramatically impaired with loss of post-synaptic junctional folds and evidence of denervation-reinnervation processes affecting the three main NMJ components [<xref ref-type="bibr" rid="CR112">112</xref>]. There may be mild reduction of the axon terminal size and post-synaptic fold simplification [<xref ref-type="bibr" rid="CR114">114</xref>]. Most patients respond beneficially to AchEI [<xref ref-type="bibr" rid="CR115">115</xref>]. In some patients the beneficial effect may be dramatic [<xref ref-type="bibr" rid="CR116">116</xref>].</p>
</sec>
<sec id="FPar32">
<title>GMPPB</title>
<p id="Par76"><italic>GMPPB</italic> encodes the catalytic enzyme GMPPB, which converts mannose-1-phosphate and GTP to GDP-mannose. GDP-mannose serves as a sugar donor [<xref ref-type="bibr" rid="CR117">117</xref>]. The amount of protein may be hardly reduced [<xref ref-type="bibr" rid="CR118">118</xref>]. <italic>GMPPB</italic> mutations manifest as mild, late-onset CMS. As with other glycosylation defects, ocular and facial muscles are largely spared and limb muscles are predominantly affected [<xref ref-type="bibr" rid="CR109">109</xref>]. Muscle weakness may be fluctuating and associated with myalgias and calf hypertrophy [<xref ref-type="bibr" rid="CR118">118</xref>]. Creatine-kinase (CK) is frequently elevated. RNS may be decremental, SF-EMG indicates a transmission defect, and EMG may be myogenic [<xref ref-type="bibr" rid="CR118">118</xref>]. Muscle weakness in patients carrying <italic>GMPPB</italic> mutations is non-proportionally prominent compared to only mild abnormalities on EMG or muscle MRI [<xref ref-type="bibr" rid="CR109">109</xref>]. On the contrary, muscle biopsy shows marked dystrophic features [<xref ref-type="bibr" rid="CR119">119</xref>]. In a review of five patients carrying <italic>GMPPB</italic> mutations, four had dystrophic features with reduced labelling for alpha-dystroglycan [<xref ref-type="bibr" rid="CR119">119</xref>]. Muscle MRI may show fatty degeneration of paraspinal, thigh adductor, and calf muscles or edema in the soleus muscle [<xref ref-type="bibr" rid="CR120">120</xref>] or selective involvement of the calves in single cases [<xref ref-type="bibr" rid="CR118">118</xref>]. Onset of clinical manifestations can be &gt;70y of age [<xref ref-type="bibr" rid="CR120">120</xref>]. Patients usually respond favourably to AchRI alone or in combination with 3,4-DAP and/or salbutamol [<xref ref-type="bibr" rid="CR119">119</xref>].</p>
</sec>
<sec id="FPar33">
<title>ALG2</title>
<p id="Par77"><italic>ALG2</italic> encodes the α-1,3-mannosyl-transferase that catalyses early steps in the asparagine-linked glycosylation pathway [<xref ref-type="bibr" rid="CR108">108</xref>]. <italic>ALG2</italic> mutations result in severely reduced expression of <italic>ALG2</italic> in muscle [<xref ref-type="bibr" rid="CR108">108</xref>]. Phenotypically, <italic>ALG2</italic> mutations manifest with infantile onset proximal muscle weakness, hypotonia, delayed motor milestones, and contractures [<xref ref-type="bibr" rid="CR108">108</xref>]. Some patients may never achieve ambulation, some may develop bulbar symptoms. Severity and progression of the LGMD-like pattern muscle affection may be highly variable even within a single family [<xref ref-type="bibr" rid="CR121">121</xref>]. RNS may be decremental. Muscle biopsy may reveal type-I-muscle fiber predominance or increased fibre-size variation [<xref ref-type="bibr" rid="CR108">108</xref>]. Muscle biopsy may show myopathic features, ragged red fibers, and a sub-sarcolemmal accumulation of abnormally structured mitochondria [<xref ref-type="bibr" rid="CR121">121</xref>].</p>
</sec>
<sec id="FPar34">
<title>ALG14</title>
<p id="Par78"><italic>ALG14</italic> encodes a protein that is thought to form a multi-glycosyl-transferase complex with ALG13 and DPAGT1 to catalyse the first of two committed steps of asparagine-linked protein glycosylation [<xref ref-type="bibr" rid="CR108">108</xref>]. Clinically, a rapidly progressive, early-onset and a benign late-onset form with variable clinical presentation can be delineated [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. The first two patients reported carrying <italic>ALG14</italic> mutations had adult-onset muscle weakness. Patients with early onset disease may present with a slightly different phenotype compared to patients with late-onset disease [<xref ref-type="bibr" rid="CR122">122</xref>]. In a recent study of 5 early-onset patients, all presented with severe muscular hypotonia, progressive cerebral atrophy, and therapy-refractory epilepsy [<xref ref-type="bibr" rid="CR122">122</xref>]. Three patients had congenital contractures [<xref ref-type="bibr" rid="CR122">122</xref>]. In 2 patients, RNS was decremental. Treatment with AchEI led only to temporary improvement. All patients died during their first year of life [<xref ref-type="bibr" rid="CR122">122</xref>].</p>
</sec>
<sec id="FPar35">
<title>DPAGT1</title>
<p id="Par79"><italic>DPAGT1</italic> encodes for an essential ER-resident enzyme catalyzing the first committed step of N-linked protein glycosylation [<xref ref-type="bibr" rid="CR123">123</xref>]. DPAGT1 is required for efficient glycosylation of AchR subunits and for efficient export of AchRs to the cell surface [<xref ref-type="bibr" rid="CR123">123</xref>]. Accordingly, the number of AchRs is reduced [<xref ref-type="bibr" rid="CR123">123</xref>]. Clinically, patients present with prominent LGMD-like weakness and minimal cranio-bulbar symptoms [<xref ref-type="bibr" rid="CR67">67</xref>]. Isolated PREPL deficiency may go along with growth hormone deficiency and cystinurea [<xref ref-type="bibr" rid="CR93">93</xref>]. Some patients present with intellectual disability and autistic features [<xref ref-type="bibr" rid="CR124">124</xref>]. Single patients may exhibit restricted ocular abduction and long finger flexor contractions [<xref ref-type="bibr" rid="CR125">125</xref>]. LF-RNS evokes a typical decrement [<xref ref-type="bibr" rid="CR67">67</xref>]. Muscle MRI may reveal T1-hyperintensities [<xref ref-type="bibr" rid="CR26">26</xref>]. Muscle biopsy in the advanced stage shows tubular aggregates [<xref ref-type="bibr" rid="CR67">67</xref>], hypoplastic endplates, fiber-type dysproportion, and degeneration of muscle fiber organelles resulting in autophagocytosis [<xref ref-type="bibr" rid="CR124">124</xref>]. Typically, AchEI and 3,4-DAP are effective [<xref ref-type="bibr" rid="CR67">67</xref>]. Neostigmine reduced the decrement but pyridostigmine had no effect [<xref ref-type="bibr" rid="CR124">124</xref>]. 3,4DAP improved the patient’s strength.</p>
</sec>
</sec>
</sec>
<sec id="Sec17">
<title>Phenotypic heterogeneity and allelic variants</title>
<p id="Par80">There are several proteins in which the same mutations may go along with phenotypic heterogeneity (allelic variants) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. For example <italic>GMPPB</italic> mutations may mimic LGMD or congenital muscular dystrophy in cases in which dystrophic features are more prominent than CMS features [<xref ref-type="bibr" rid="CR109">109</xref>]. In these patients the NMJ may be morphologically normal [<xref ref-type="bibr" rid="CR109">109</xref>]. Mutations in <italic>GMPPB</italic> not only manifest as CMS but also as dystroglycanopathy [<xref ref-type="bibr" rid="CR117">117</xref>]. <italic>PLEC</italic> mutations may not only cause CMS but also LGMD2Q, pyloric atresia, or epidermiolysis bullosa. Mutations in <italic>SLC25A7</italic> not only cause CMS but also AD forms of distal motor neuropathy [<xref ref-type="bibr" rid="CR20">20</xref>]. Mutations in <italic>DPAGT1</italic> also cause congenital glycosylation-I defect and LGMD [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, there is intra- and inter-familial phenotypic heterogeneity despite the same genotype and a possible gender effect [<xref ref-type="bibr" rid="CR14">14</xref>]. It is also important to mention that primary myopathies may go along with secondary transmission disease, which does not represent CMS, such as in patients with congenital myopathy due to <italic>TPM2</italic> mutations [<xref ref-type="bibr" rid="CR126">126</xref>], or patients carrying mutations in <italic>KLHL40, BIN1, DNM2, MTM1, TPM3</italic>, or <italic>RYR1</italic>. Importantly, secondary transmission disease frequently responds beneficially to AchEI.</p>
</sec>
<sec id="Sec18">
<title>Diagnosis</title>
<p id="Par81">Diagnosing CMS relies on a thorough work-up by means of the history, clinical exam, blood tests, electrophysiological investigations, lung function tests, polysomnography, the tensilon test, eventually muscle biopsy, and the confirmation of a heterocygote or biallelic pathogenic variant in one of the 32 CMS genes. A CMS should be generally suspected if 1. there is easy fatigability or permanent weakness, most frequently in the ocular, facial, bulbar, axial, respiratory, or limb muscles with onset from birth to childhood; 2. the family history is positive for clinical manifestations of CMS; 3. history and clinical exam suggest myasthenia gravis but where AchR-, MUSK-, and LRP4-antibody tests are negative; 4. LF-RNS evokes a decrement of &gt; 10% or if SF-EMG shows increased jitter or blockings; 5. clinical manifestations respond to AchEI; 6. there is a lack of improvement upon immunosuppressive therapy; 7. the family history suggests an AD/AR transmitted disease; 8. there is absence of a major pathology on muscle biopsy; and if 9. a specific syndrome (e.g. Escobar syndrome, Pierson syndrome (eye disease and nephropathy)) is present [<xref ref-type="bibr" rid="CR24">24</xref>]. Mixing phenotype and age at onset, three phenotypes can be differentiated, which are the infantile-onset type, childhood-onset type, and the LGMD-type [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
<sec id="Sec19">
<title>History</title>
<p id="Par82">In case the history can be taken, patients may report easy fatigability, fluctuating or permanent weakness of ocular, bulbar, facial, axial, or limb muscles, double vision, ptosis, dysarthria, dysphagia, hypoacusis, head drop, or respiratory insufficiency. Patients may also recognise dysmorphism, they may report neuropathic pain, seizures, pterygia, contractures, hyperlaxity of joints, abnormal speech, cognitive impairment, respiratory insufficiency, or skeletal deformities.</p>
</sec>
<sec id="Sec20">
<title>Clinical exam</title>
<p id="Par83">The neurological exam may be normal or abnormal.</p>
<sec id="FPar36">
<title>Muscular features</title>
<p id="Par84">Muscular abnormalities include ptosis, ophthalmoparesis, facial weakness, bulbar weakness (dysarthria, dysphagia), axial weakness (head drop, camptocormia), dyspnea, limb weakness, hypotonia, or reduced tendon reflexes. Rarely, patients may present with muscle wasting, particularly of limb muscles [<xref ref-type="bibr" rid="CR81">81</xref>]. Atrophy of the skeletal muscles is particularly reported in <italic>MUSK</italic>-related CMS [<xref ref-type="bibr" rid="CR81">81</xref>].</p>
</sec>
</sec>
<sec id="Sec34">
<title>Non-muscle signs</title>
<sec id="FPar38">
<title>Facial dysmorphism</title>
<p id="Par86">There are a number of dysmorphic features that occur in specific CMS subtypes [<xref ref-type="bibr" rid="CR54">54</xref>]. These include long face (<italic>SYB1</italic>) [<xref ref-type="bibr" rid="CR7">7</xref>], hypertelorism (<italic>SYB1</italic>) [<xref ref-type="bibr" rid="CR7">7</xref>], narrow jaw (<italic>RAPSN</italic>), saddle nose (<italic>SYB1</italic>) [<xref ref-type="bibr" rid="CR7">7</xref>], and high-arched palate (<italic>SCN4A</italic>) [<xref ref-type="bibr" rid="CR96">96</xref>]. In a Saudi female carrying a <italic>COLQ</italic> mutation, microcephaly was reported (Table <xref ref-type="table" rid="Tab3">3</xref>) [<xref ref-type="bibr" rid="CR41">41</xref>]. Microcephaly was also reported in <italic>MUNC13–1</italic>-related CMS.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Typical clinical manifestations of CMS subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Phenotypic feature</th><th>CMS subtypes</th></tr></thead><tbody><tr><td colspan="2">Myopathic</td></tr><tr><td> LGMD-type</td><td>COLQ, DOK7, MUSK, GFPT1, ALG2, ALG14, DPAGT1</td></tr><tr><td> Respiratory insufficiency</td><td>SLC18A3, SYB1, COLQ, LAMB2, CHRNB1, CHRND, CHRNE, CHRNG, MUSK, NYO9A, LRP4, COL13A1, SCN4A, RAPS</td></tr><tr><td> Episodic apnea</td><td>CHAT, MUSK, SLC5A7, SLC25A1, RAPSN, COLQ</td></tr><tr><td> Head drop</td><td>AGRN</td></tr><tr><td> Myopathic EMG</td><td>CHRNB1, ALG2, PLEC1, GMPPB</td></tr><tr><td> Double response</td><td>CHRNE, COLQ, SCCMS, ACHE-deficiency, CHRNA1, CHRNB1, CHRND</td></tr><tr><td colspan="2">Non-myopathic</td></tr><tr><td> Cognitive dysfunction</td><td>SLC25A7, DPAGT1, SNAP25, COL13A1, MYO9A, CHRNB1, CHRND</td></tr><tr><td> Facial tics</td><td>LAMA5</td></tr><tr><td> Cerebral atrophy</td><td>SCN4A, ALG14</td></tr><tr><td> Agenesis of corpus callosu</td><td>SLC25A1</td></tr><tr><td> Epilepsy</td><td>ALG14, SLC25A1, MUNC13–1</td></tr><tr><td> Facial dysmorphism</td><td>SYB1, RAPSN, SCN4A, COLQ</td></tr><tr><td> Myopia</td><td>LAMA5</td></tr><tr><td> Hypoacusis</td><td>SLC25A1, SYT2</td></tr><tr><td> Vocal cord paralysis</td><td>COLQ, DOK7</td></tr><tr><td> Neuropathy</td><td>SYT2, SLC25A7</td></tr><tr><td> Arthrogryposis multiplex</td><td>SLC5A7, CHRNG</td></tr><tr><td> Contractures</td><td>SNAP25, VAMP1, CHRNA1, ALG2, ALG14, RAPSN, CHRND, CHRNG, CHAT</td></tr><tr><td> Scoliosis</td><td>COLQ, CHRNE, VAMP1</td></tr><tr><td> Hyperlordosis, hyperkyphosis</td><td>SCNA4, RAPSN, SYB1</td></tr><tr><td> Adduction deformity of knees</td><td>SCN4A</td></tr><tr><td> Cubitus valgus</td><td>PLEC1</td></tr><tr><td> Foot deformity</td><td>SYT2, RAPSN, CHRNG, SLC25A1, COLQ</td></tr><tr><td> Hyperlaxity of joints</td><td>SYT2, VAMP1, COL13A1</td></tr><tr><td> Cutaneous blisters</td><td>PLEC1</td></tr><tr><td> Pterygia</td><td>CHRNG</td></tr><tr><td> Systolic dysfunction</td><td>SLC18A3</td></tr><tr><td> Pierson syndrome</td><td>LAMB2</td></tr><tr><td> Cerebellar ataxia</td><td>SNAP25</td></tr><tr><td> Laryngospasm</td><td>SCN4A</td></tr><tr><td> Deterioration in cold water</td><td>SLC18A3</td></tr><tr><td> Hip dysplasia</td><td>SYT2</td></tr><tr><td> Cryptorchism</td><td>CHRNG</td></tr><tr><td> Arachnodactylia</td><td>CHRNG</td></tr><tr><td> Microcephaly</td><td>MUNC13–1</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="FPar39">
<title>Skeletal abnormalities</title>
<p id="Par87">Hyperlordosis or hyperkyphosis were reported in patients carrying <italic>SCN4A</italic> [<xref ref-type="bibr" rid="CR97">97</xref>], <italic>RAPSN</italic> [<xref ref-type="bibr" rid="CR101">101</xref>], or <italic>SYB1</italic> [<xref ref-type="bibr" rid="CR7">7</xref>] mutations. Scoliosis may occur in <italic>CHRNE</italic>-related CMS [<xref ref-type="bibr" rid="CR27">27</xref>] but also in <italic>COLQ</italic>-related CMS [<xref ref-type="bibr" rid="CR43">43</xref>]. Foot deformities include pes cavus (hollow foot), pes planus, or hammertoes (<italic>SYT2</italic>-related CMS [<xref ref-type="bibr" rid="CR127">127</xref>], <italic>SLC25A1</italic>). Club feet have been found in <italic>RAPSN</italic>-related CMS [<xref ref-type="bibr" rid="CR54">54</xref>], and <italic>COLQ</italic>-related CMS [<xref ref-type="bibr" rid="CR41">41</xref>]. In <italic>SCN4A</italic>-related CMS adduction deformity of the knees and ankles were reported [<xref ref-type="bibr" rid="CR96">96</xref>]. Cubitus valgus was reported in <italic>PLEC1</italic>-associated CMS [<xref ref-type="bibr" rid="CR106">106</xref>]. Hyperlaxity of joints and hip dysplasia may occur in <italic>SYT2</italic>-related CMS [<xref ref-type="bibr" rid="CR32">32</xref>]. Joint laxity and kyphoscoliosis were reported in association with <italic>VAMP1</italic> [<xref ref-type="bibr" rid="CR31">31</xref>] and <italic>COL13A1</italic> variants.</p>
</sec>
<sec id="FPar40">
<title>Cognitive impairment/neurodevelopmental delay</title>
<p id="Par88">Cognitive dysfunction is only rarely a manifestation of a CMS phenotype. Mild to severe cognitive impairment has been reported in patients carrying mutations in the <italic>SLC5A7</italic> gene, <italic>DPAGT1</italic> gene [<xref ref-type="bibr" rid="CR124">124</xref>], <italic>SNAP25</italic> gene [<xref ref-type="bibr" rid="CR30">30</xref>], <italic>COL13A1</italic> gene [<xref ref-type="bibr" rid="CR52">52</xref>], <italic>MYO9A</italic> gene [<xref ref-type="bibr" rid="CR86">86</xref>], <italic>MUNC13–1</italic> gene, and in <italic>SCN4A</italic>-related CMS [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. In a study of 6 families, half of the probands carrying a <italic>SLC25A7</italic> mutation had mild cognitive impairment [<xref ref-type="bibr" rid="CR20">20</xref>]. Recently, mutations in the <italic>SLC18A3</italic> gene have been shown to manifest as neurodevelopmental delay with cerebral atrophy [<xref ref-type="bibr" rid="CR21">21</xref>]. Mutations in this gene may be also associated with infantile lethality [<xref ref-type="bibr" rid="CR21">21</xref>]. Mild cerebral atrophy was reported in <italic>SCN4A</italic>-related CMS [<xref ref-type="bibr" rid="CR96">96</xref>] and in <italic>ALG14</italic>-related CMS [<xref ref-type="bibr" rid="CR123">123</xref>].</p>
</sec>
<sec id="FPar41">
<title>Neuropathy</title>
<p id="Par89">Mutations in CMS genes, such as in <italic>SYT2</italic>, not only manifest in the skeletal muscle but also in the peripheral nerves as polyneuropathy [<xref ref-type="bibr" rid="CR128">128</xref>]. Also <italic>SLC5A7</italic> mutations may manifest with distal neuropathy [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
</sec>
<sec id="FPar42">
<title>Epilepsy</title>
<p id="Par90">There are a number of patients diagnosed with CMS who also had epilepsy. Epilepsy was reported in patients with CMS due to <italic>SLC25A1</italic> mutations [<xref ref-type="bibr" rid="CR107">107</xref>], due to <italic>MUNC13–1</italic> mutations, or due to <italic>ALG14</italic> mutations [<xref ref-type="bibr" rid="CR122">122</xref>].</p>
</sec>
<sec id="FPar43">
<title>Others</title>
<p id="Par91">Cutaneous blisters of the dermis or the mucosa may be found in <italic>PLEC1</italic>-related CMS [<xref ref-type="bibr" rid="CR106">106</xref>]. Agenesis of the corpus callosum and hearing loss have been reported in <italic>MUNC13–1</italic>-related [<xref ref-type="bibr" rid="CR36">36</xref>] and <italic>SLC25A1</italic>-related CMS [<xref ref-type="bibr" rid="CR107">107</xref>]. Two patients with <italic>COLQ</italic>-related CMS manifested with vocal cord paralysis [<xref ref-type="bibr" rid="CR42">42</xref>]. Single patients with AchR-related CMS may develop pterygia. In <italic>SLC18A3</italic>-related CMS, systolic dysfunction was reported [<xref ref-type="bibr" rid="CR29">29</xref>]. In a female with a <italic>LAMA5</italic>-variant, myopia and facial tics were described [<xref ref-type="bibr" rid="CR51">51</xref>].</p>
</sec>
</sec>
<sec id="Sec21">
<title>Blood tests</title>
<p id="Par92">CK may be normal [<xref ref-type="bibr" rid="CR81">81</xref>] or mildly elevated (maximally 10 times the upper limit) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], with the exception of <italic>GMPPB</italic>-related CMS. Antibodies against AchR, MUSK, or RLP4 are usually absent, being one of the diagnostic criteria for CMS [<xref ref-type="bibr" rid="CR129">129</xref>].</p>
</sec>
<sec id="Sec22">
<title>Electrophysiologic evaluation</title>
<p id="Par93">The most important electrophysiological investigation to support the CMS diagnosis are LF-RNS and HF-RNS. LF-RNS usually shows a decrement and only rarely an increment. If RNS is normal in two limb muscles, RNS of the facial muscles should be tried. HF-RNS usually shows an increment and only rarely a decrement [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. In patients carrying <italic>SCN4A</italic> variants, LF-RNS may be normal but may show a decremental response at higher stimulus rates [<xref ref-type="bibr" rid="CR94">94</xref>]. Pre-synaptic CMS may not only be detected upon a profound decrement to LF-RNS but also by a prolonged period of post-activation exhaustion (decreased neuromuscular transmission on RNS after previous intense muscle contraction) [<xref ref-type="bibr" rid="CR29">29</xref>]. In patients with <italic>RAPSN</italic>-related CMS, HF-RNS was followed by a decrement instead of the expected increment [<xref ref-type="bibr" rid="CR130">130</xref>]. If RNS is normal, muscle contractions or exercise should be performed prior to the test. Instead of voluntary muscle contractions, 10 Hz stimulation during 5-10 min prior to LF-RNS may help to unmask an abnormal decrement or increment. In patients carrying <italic>SYT1</italic> mutations, CMAP amplitudes may be initially low but may markedly increase after forced exercise, like in Lambert-Eaton myasthenic syndrome [<xref ref-type="bibr" rid="CR127">127</xref>]. If RNS is still normal, but still suspicion of a CMS, single fiber EMG is indicated, which may show increased jitter or increased number of blockings despite normal RNS [<xref ref-type="bibr" rid="CR107">107</xref>]. Another test to unmask a NMJ defect is application of a single stimulus, which may be followed by a spontaneous second one (double response). The double response phenomenon can be typically observed in <italic>COLQ</italic>-related CMS and in SCCMS. In some patients needle-EMG may be myopathic [<xref ref-type="bibr" rid="CR10">10</xref>]. Contrary to patients with periodic paralysis, myotonia may be absent on EMG in <italic>SCN4A</italic>-related CMS [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
</sec>
<sec id="Sec23">
<title>Lung function, polysomnography</title>
<p id="Par94">Essential investigations to assess respiratory functions and to identify patients with nocturnal hypoventilation include lung function tests, arterial blood gas analysis, and polysomnography. Polysomnography is important to detect sleep disorders due to nocturnal apnoe/hypopnea recently reported in <italic>COLQ</italic>- and <italic>RAPSN</italic>-related CMS [<xref ref-type="bibr" rid="CR131">131</xref>]. Symptoms indicative of nocturnal hypoventilation include daytime headache, restless sleep, impaired concentration, snoring, recurrent respiratory infections, or weight loss [<xref ref-type="bibr" rid="CR6">6</xref>]. Applicability of lung function tests is restricted to cooperative patients. Non-cooperating patients may be investigated only by blood gas analyses and polysomnography.</p>
</sec>
<sec id="Sec24">
<title>Tensilon test</title>
<p id="Par95">Though testing with edrophonium is frequently proposed, there are hardly reports about the details in patients with CMS. Generally, the test should be carried out only on an intermediate care unit (ICU) [<xref ref-type="bibr" rid="CR6">6</xref>]. Initially, 2 mg should be applied, followed by another 2-5 mg in patients &gt; 30 kg [<xref ref-type="bibr" rid="CR6">6</xref>]. The dosage may be less in neonates and infants. The strongest effect will be achieved after 30s. Before the test, it is important to define an endpoint, such as ptosis, ophthalmoparesis, or weakness of limb muscles. Alternatively to edrophonium, pyridostigmine can be applied orally. Some patients with <italic>CHRNE</italic> mutations may show a striking response to the ice pack test [<xref ref-type="bibr" rid="CR64">64</xref>].</p>
</sec>
<sec id="Sec25">
<title>Muscle biopsy</title>
<p id="Par96">Muscle biopsy is normal in the majority of the cases. However, in glycosylation disorders due to mutations in the <italic>GFPT1</italic> gene tubular aggregates with synaptopathy and dramatic loss of post-synaptic functional folds and evidence of denervations/reinnervation processes affecting the three main NMJ components can be found [<xref ref-type="bibr" rid="CR112">112</xref>]. In patients carrying <italic>MUSK</italic> mutations, increased fiber-size variability has been reported [<xref ref-type="bibr" rid="CR81">81</xref>]. Patients with <italic>COLQ</italic>- or <italic>GMPPB</italic>-related CMS may show dystrophic features on muscle biopsy [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. Patients with <italic>COLQ</italic>- and <italic>ALG2</italic>-related CMS may show type-I-fiber predominance [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR108">108</xref>].</p>
</sec>
<sec id="Sec26">
<title>Genetic testing</title>
<p id="Par97">The most important investigations for diagnosing CMS are genetic tests. Different approaches for genetic testing can be applied, including single gene testing, multiple gene panel testing, or comprehensive genetic testing (WES, whole genome sequencing (WGS)) [<xref ref-type="bibr" rid="CR6">6</xref>]. Single gene testing is indicated if a single gene accounts for a large proportion of the phenotype or if the phenotype and ancestry suggest a mutation in a particular gene as most likely. Sequencing of the gene of interest is carried out first, followed by gene-targeted deletion / duplication analysis [<xref ref-type="bibr" rid="CR6">6</xref>]. Particular phenotypic features (apnea, non-response to AchEI, double response, increment on RNS, dysmorphism, foot deformities, neuropathy, epilepsy, contractures, AD/AR trait, or the ethnic origin (Maghreb, Roma, Spain/Portugal, Central/Western Europe) may guide the clinician to suspect a particular CMS subtype. For example, AD transmission is indicative of <italic>SYT1-, SLC5A7-, SNAP25</italic>-related, and SCCMS subtypes, usually present after adolescence with mild phenotypes. Only rare cases present in early life and become severely disabled in the first decade [<xref ref-type="bibr" rid="CR18">18</xref>]. On the contrary, FCCMS usually present in early childhood with an infantile phenotype.</p>
<p id="Par98">Due to the phenotypic heterogeneity, however, multi-gene panels are emerging as first-line diagnostic tool. If serial single gene testing or multi-gene panels fail to establish the diagnosis, WES should be considered [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
</sec>
<sec id="Sec27">
<title>Differential diagnoses</title>
<p id="Par99">Differential diagnoses that have to be excluded before diagnosing CMS in adults include myasthenia gravis, motor neuron disease, including Kennedy disease, limb girdle muscular dystrophy, facio-scapulo-humeral muscular dystrophy, mitochondrial disorders, and hereditary neuropathies (Table <xref ref-type="table" rid="Tab4">4</xref>). Myasthenia gravis usually has its onset in adulthood, however, when patients with myasthenia are young and sero-negative, differentiation from CMS can be challenging. Differential diagnoses that have to be excluded before diagnosing CMS in infants or children include transient neonatal myasthenia gravis, spinal muscular atrophy, congenital muscular dystrophy, congenital myotonic dystrophy-1, early-onset mitochondrial disorder, congenital myopathy, brainstem lesions, Moebius syndrome, and botulism (Table <xref ref-type="table" rid="Tab4">4</xref>). Clinical phenotypes of CMS share significant overlap in their clinical presentations with mitochondrial disorders, leading to challenges in establishing the correct diagnosis [<xref ref-type="bibr" rid="CR45">45</xref>].<table-wrap id="Tab4"><label>Table 4</label><caption><p>Differential diagnoses of CMS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Differential diagnosis</th><th>Early onset</th><th>Adult onset</th></tr></thead><tbody><tr><td>FADS</td><td>yes</td><td>no</td></tr><tr><td>Periodic paralysis (SCNA4)</td><td>yes</td><td>yes</td></tr><tr><td>CDG</td><td>yes</td><td>no</td></tr><tr><td>Spinal muscular atrophy</td><td>yes</td><td>yes</td></tr><tr><td>Mitochondrial disorders</td><td>yes</td><td>yes</td></tr><tr><td>Myasthenia gravis</td><td>no</td><td>yes</td></tr><tr><td>Transient neonatal myasthenia</td><td>yes</td><td>no</td></tr><tr><td>Congenital muscular dystrophy</td><td>yes</td><td>no</td></tr><tr><td>Congenital myopathies</td><td>yes</td><td>no</td></tr><tr><td>Congenital myotonic dystrophy</td><td>yes</td><td>no</td></tr><tr><td>Brain stem abnormalities</td><td>yes</td><td>yes</td></tr><tr><td>Moebius syndrome</td><td>yes</td><td>no</td></tr><tr><td>(Infantile) botulism</td><td>yes</td><td>yes</td></tr><tr><td>Kennedy disease</td><td>no</td><td>yes</td></tr><tr><td>LGMD</td><td>yes</td><td>yes</td></tr><tr><td>FSH-MD</td><td>yes</td><td>yes</td></tr><tr><td>Hereditary neuropathies</td><td>yes</td><td>yes</td></tr></tbody></table><table-wrap-foot><p><italic>FADS</italic> Fetal akinesia deformation sequence, <italic>CDG</italic> congenital disease of glycosylation, <italic>LGMD</italic> limb girdle muscular dystrophy, <italic>FSH-MD</italic> facio-scapulo-humeral muscular dystrophy</p></table-wrap-foot></table-wrap></p>
</sec>
</sec>
<sec id="Sec28">
<title>Therapy</title>
<p id="Par100">Therapy of CMS is not standardised due to the low number of patients and thus the lack of sufficiently powered treatment studies. Additionally, the genotypic and phenotypic heterogeneity makes it difficult to recruit homogenous groups required for treatment studies. Due to the rarity of CMS, therapy trials will meet the requirements for an appropriately designed treatment study only when applying an international, multicentre design. Generally, treatment may be classified as symptomatic or causal, invasive or non-invasive, or as established or experimental. Since no causal treatment for CMS is available, only symptomatic measures can be offered to these patients. Among the non-invasive symptomatic measures, drug treatment and non-drug treatment can be differentiated. Disadvantage of most reports is that dosages of agents applied, type of combinations, and duration of drug therapy are frequently not or insufficiently reported. There are also hardly reports available about side effects of the various agents applied.</p>
<sec id="Sec29">
<title>Non-invasive symptomatic treatment</title>
<sec id="FPar44">
<title>Drugs</title>
<p id="Par101">There are several drugs available, which are applied to CMS patients but since some of them may exhibit severe side effects, these drugs need to be applied with caution until there is clear evidence that a particular patient profits from such compounds. Only in case of an emergency in a suspected CMS, drugs can be tried without previous genetic confirmation of the diagnosis.</p>
</sec>
<sec id="FPar45">
<title>AchE-inhibitors</title>
<p id="Par102">AchEI are the drugs most frequently given to CMS patients (Table <xref ref-type="table" rid="Tab5">5</xref>) but may not be effective in each of them (Table <xref ref-type="table" rid="Tab5">5</xref>) [<xref ref-type="bibr" rid="CR42">42</xref>]. AchEI may even deteriorate clinical manifestations in certain subtypes of CMS, such as in <italic>COLQ-, LAMB2-, DOK7-, MUSK</italic>-, or <italic>LRP4</italic>-related CMS. In case of an infection, prophylactic application of AchEI may be recommended. Prophylactic AchEI together with antibiotics may prevent the occurrence of episodic apnea and respiratory insufficiency.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Effectiveness of drug treatment in the 32 CMS subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CMS subtype</th><th>AchEI&amp;</th><th>3,4-DAP</th><th>SALB</th><th>ALB</th><th>Ephed</th><th>Fluoxetine</th></tr></thead><tbody><tr><td colspan="7">Pre-synaptic</td></tr><tr><td> SLC5A7</td><td>e</td><td>nr</td><td>e</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> CHAT</td><td>pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SLC18A3</td><td>pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SNAP25</td><td>ie</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> VAMP1</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SYB1</td><td>pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SYT2</td><td>pe</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> MUNC13–1</td><td>pe</td><td>pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td colspan="7">Synaptic</td></tr><tr><td> COLQ</td><td>ie</td><td>pe</td><td>e</td><td>nr</td><td>e</td><td>nr</td></tr><tr><td> LAMB2</td><td>ie</td><td>pe</td><td>e</td><td>nr</td><td>e</td><td>nr</td></tr><tr><td> LAMA5</td><td>e</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> COL13A1</td><td>ie</td><td>e</td><td>e</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td colspan="7">Post-synaptic</td></tr><tr><td> CHRNA1</td><td>e/pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> CHRNB1</td><td>ie</td><td>nr</td><td>nr</td><td>nr</td><td>pe</td><td>e</td></tr><tr><td> CHRND</td><td>pe</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> CHRNE</td><td>e/ie</td><td>ie</td><td>e</td><td>e</td><td>nr</td><td>e</td></tr><tr><td> CHRNG</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> FCCMS</td><td>e</td><td>e<sup>a</sup></td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SCCMS</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>e</td></tr><tr><td> DOK7</td><td>ie</td><td>nr</td><td>e</td><td>e</td><td>e</td><td>nr</td></tr><tr><td> MUSK</td><td>ie</td><td>ie/e</td><td>e</td><td>pe</td><td>ie</td><td>nr</td></tr><tr><td> MYO9A</td><td>e</td><td>e<sup>a</sup></td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> AGRN</td><td>ie</td><td>nr</td><td>nr</td><td>nr</td><td>e</td><td>nr</td></tr><tr><td> LRP4</td><td>ie</td><td>nr</td><td>nr</td><td>e</td><td>nr</td><td>nr</td></tr><tr><td> PREPL</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SCN4A</td><td>pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> RAPSN</td><td>e<sup>b</sup></td><td>e</td><td>nr</td><td>nr</td><td>e</td><td>nr</td></tr><tr><td> PLEC1</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> SLC25A1</td><td>ie</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td colspan="7">Glycosilation defect</td></tr><tr><td> GFPT1</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> GMPPB</td><td>e</td><td>e<sup>a</sup></td><td>e</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> ALG2</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> ALG14</td><td>pe</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr><tr><td> DPAGT1</td><td>e</td><td>e</td><td>nr</td><td>nr</td><td>nr</td><td>nr</td></tr></tbody></table><table-wrap-foot><p>SALB: salbutamol, ALB: albuterole, Ephed: ephedrine, pe: partially effective, nr: not reported, e: effective, ie: ineffective, <sup>a</sup>: in combination with AchEI, <sup>b</sup>: in combination with 3,4-DAP, &amp;: in <italic>COLQ-, LAMB2-, DOK7-, MUSK</italic>-, and <italic>LRP4</italic>-related CMS AchEI may deteriorate the clinical manifestations</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="FPar46">
<title>4-Diaminopyridine</title>
<p id="Par103">The most frequently applied alternative drug to AchEI or the one most frequently given in combination with AchEI is 3,4-DAP. 3,4-DAP increases the amount of acetylcholine released to the synaptic cleft. Additionally, it prolongs the presynaptic action potential. 3,4-DAP is not only effective in pre-synaptic but also in post-synaptic CMS [<xref ref-type="bibr" rid="CR129">129</xref>]. 3,4-DAP may have only a mild beneficial effect in <italic>COLQ</italic>-related or <italic>LAMB2</italic>-related CMS (Table <xref ref-type="table" rid="Tab5">5</xref>) [<xref ref-type="bibr" rid="CR42">42</xref>]. 3,4-DAP may be ineffective in <italic>CHRNE</italic>- or <italic>MUSK</italic>-related CMS (Table <xref ref-type="table" rid="Tab5">5</xref>). 3,4-DAP may be detrimental in FCCMS due to AR loss-of-function mutations and should be avoided in these conditions [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
</sec>
<sec id="FPar47">
<title>Salbutamol</title>
<p id="Par104">Salbutamol is a β2-mimetic, which has been reported beneficial in <italic>SLC5A7-, COLQ</italic>-, <italic>CHRNE-, DOK7-, MUSK-, COL13A1-,</italic> and <italic>GMPPB-</italic>related CMS (Table <xref ref-type="table" rid="Tab5">5</xref>) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p>
</sec>
<sec id="FPar48">
<title>Albuterol</title>
<p id="Par105">Albuterol is a bronchodilator and an alternative to ephedrine and has a beneficial role in <italic>CHRNE</italic>- and <italic>MUSK</italic>-related CMS (Table <xref ref-type="table" rid="Tab5">5</xref>).</p>
</sec>
<sec id="FPar49">
<title>Ephedrine</title>
<p id="Par106">Ephedrine is an alkaloid from the group of phenyl-ethyl-amines, originating from the plant ephedra. It is used in medicine as a sympathomimetic agent, for asthma, as a decongestant, and in ophthalmology as a supplement of atropine. Ephedrine is usually well tolerated. It has been reported effective in <italic>COLQ-, LAMB2-, DOK7</italic>-, and <italic>AGRN</italic>-related CMS (Table <xref ref-type="table" rid="Tab5">5</xref>). In a patient with <italic>COLQ</italic>-related CMS manifesting as vocal cord paralysis, hypotonia, ptosis, ophthalmoparesis, and facial diplegia, ephedrine was highly effective [<xref ref-type="bibr" rid="CR42">42</xref>]. Ephedrine was ineffective in <italic>MUSK</italic>-related CMS [<xref ref-type="bibr" rid="CR85">85</xref>].</p>
</sec>
<sec id="FPar50">
<title>Fluoxetine</title>
<p id="Par107">Reports about the effect of fluoxetine in CMS are conflicting. While a beneficial effect has been reported in <italic>CHRNB1</italic> and <italic>CHRNE</italic>-related CMS (Table <xref ref-type="table" rid="Tab5">5</xref>), fluoxetine worsened the clinical manifestations in <italic>MYO9A</italic>- and <italic>RAPSN</italic>-related CMS. Fluoxetine has been reported beneficial for muscle weakness in patients with SCCMS [<xref ref-type="bibr" rid="CR132">132</xref>].</p>
</sec>
<sec id="FPar51">
<title>Others/experimental</title>
<p id="Par108">Only single reports are available about the effect of acetazolamide, quinidine, and atracurium. Recently, zonisamide has been shown beneficial in experimental CMS, being attributed to its nerve-sprouting activity [<xref ref-type="bibr" rid="CR133">133</xref>].</p>
</sec>
<sec id="FPar52">
<title>Non-drug treatment</title>
<p id="Par109">Non-invasive, non-drug treatment relies on physiotherapy, speech therapy, and occupational therapy. To warrant mobility, orthoses, walkers, or wheel chairs may be used. Generally, patients with CMS should avoid strenuous exercise or infections, which may exacerbate symptoms of a transmission disease. NIPPV either during the night or the entire day may support insufficient self-breathing. In animals, antisense oligonucleotides (AONs) have been shown to be beneficial in <italic>CHRNA1</italic>-related CMS [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
</sec>
</sec>
<sec id="Sec30">
<title>Invasive measures</title>
<p id="Par110">In case of dysphagia, failure-to-thrive, or a nutritional disturbance, implantation of a PEG may be necessary. In case of respiratory insufficiency without the possibility of a NIPPV, intubation and mechanical ventilation may be indicated. Severe, symptomatic scoliosis may require surgical spinal correction [<xref ref-type="bibr" rid="CR49">49</xref>]. Foot deformities may require surgical corrections.</p>
</sec>
<sec id="Sec31">
<title>Pregnancy and CMS</title>
<p id="Par111">Pregnancy has been reported to exacerbate clinical manifestations of CMS [<xref ref-type="bibr" rid="CR134">134</xref>]. In a study of 17 pregnancies of females from 8 families with a CMS it turned out that pregnancy deteriorated clinical manifestations of CMS [<xref ref-type="bibr" rid="CR135">135</xref>]. In most cases, affected females recovered to the status quo ante within six months postnatally [<xref ref-type="bibr" rid="CR135">135</xref>]. The outcome of neonates born to females with CMS is fair except in females with SCCMS [<xref ref-type="bibr" rid="CR135">135</xref>]. To warrant a good outcome from pregnancy, close neurological surveillance is necessary.</p>
</sec>
</sec>
<sec id="Sec32">
<title>Prognosis and outcome</title>
<p id="Par112">Prospective outcome studies are not available but in several observational studies, case studies, and case reports, the outcome has been mentioned. In a study of 79 CMS patients, those carrying a <italic>DOK7</italic> mutation had the worst outcome [<xref ref-type="bibr" rid="CR134">134</xref>]. Among the 8 patients being wheel-chair-bound and ventilated, 6 carried a <italic>DOK7</italic> variant [<xref ref-type="bibr" rid="CR134">134</xref>]. Since the clinical presentation is highly variable, also the outcome and prognosis may vary considerably between the various CMS types. The outcome is further influenced by acute deteriorations due to infections, fever, or psychosocial stress.</p>
</sec>
</sec>
<sec id="Sec33">
<title>Conclusions</title>
<p id="Par113">Currently, 8 pre-synaptic, 4 synaptic, 15 post-synaptic, and 5 glycosilation defects are known to cause CMS. The most frequently reported CMS subtypes are <italic>COLQ-, CHRNE-, RAPSN-, DOK7</italic>-, and <italic>CHAT</italic>-related CMS (Table <xref ref-type="table" rid="Tab1">1</xref>). Though CMS are congenital in the majority of the cases, it becomes increasingly evident that in some subtypes the onset may be in early or even late adulthood. However, severity of the disease is usually more pronounced in early-onset subtypes. Due to their intra- and inter-familial phenotypic heterogeneity, CMSs can be easily mixed up with other neuromuscular disorders, particularly LGMDs and mitochondrial disorders. A number of promising proposals have been launched for the treatment of certain CMS subtypes during recent years. They should be further evaluated to find out if they are also effective in other CMS subtypes. These measures include the application of a gene therapy with AONs and the application of zonisamide, which may trigger axonal sprouting. Whenever patients with myasthenic symptoms do not present with AchR- or MUSK-antibodies, do not respond to immunosuppressive treatment, have a positive family history for their phenotype, and show impaired neuromuscular transmission upon RNS or SF-EMG, a CMS should be considered.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AchEI</term>
<def>
<p id="Par5">Acetylcholine-esterase inhibitors</p>
</def>
</def-item>
<def-item>
<term>AchR</term>
<def>
<p id="Par6">Acetylcholine-receptor</p>
</def>
</def-item>
<def-item>
<term>AD</term>
<def>
<p id="Par7">Autosomal dominant</p>
</def>
</def-item>
<def-item>
<term>AON</term>
<def>
<p id="Par8">Antisense-oligonucleotide</p>
</def>
</def-item>
<def-item>
<term>AR</term>
<def>
<p id="Par9">Autosomal recessive</p>
</def>
</def-item>
<def-item>
<term>CMAP</term>
<def>
<p id="Par10">Compound muscle action potential</p>
</def>
</def-item>
<def-item>
<term>CMD</term>
<def>
<p id="Par11">Congenital muscular dystrophy</p>
</def>
</def-item>
<def-item>
<term>CMS</term>
<def>
<p id="Par12">Congenital myasthenic syndrome</p>
</def>
</def-item>
<def-item>
<term>DAP</term>
<def>
<p id="Par13">Diaminopyridine</p>
</def>
</def-item>
<def-item>
<term>DNA</term>
<def>
<p id="Par14">Desoxiribonucleic acid</p>
</def>
</def-item>
<def-item>
<term>EDB</term>
<def>
<p id="Par15">Epidermiolysis bullosa</p>
</def>
</def-item>
<def-item>
<term>EMG</term>
<def>
<p id="Par16">Electromyography</p>
</def>
</def-item>
<def-item>
<term>ER</term>
<def>
<p id="Par17">Endoplasmatic reticulum</p>
</def>
</def-item>
<def-item>
<term>FADS</term>
<def>
<p id="Par18">Fetal akinesia deformation sequence</p>
</def>
</def-item>
<def-item>
<term>ICU</term>
<def>
<p id="Par19">Intermediate care unit</p>
</def>
</def-item>
<def-item>
<term>LF-RNS</term>
<def>
<p id="Par20">Low-frequency RNS</p>
</def>
</def-item>
<def-item>
<term>LGMD</term>
<def>
<p id="Par21">Limb girdle muscular dystrophy</p>
</def>
</def-item>
<def-item>
<term>MRI</term>
<def>
<p id="Par22">Magnetic resonance imaging</p>
</def>
</def-item>
<def-item>
<term>NIPPV</term>
<def>
<p id="Par23">Non-invasive positive pressure ventilation</p>
</def>
</def-item>
<def-item>
<term>NMJ</term>
<def>
<p id="Par24">Neuromuscular junction</p>
</def>
</def-item>
<def-item>
<term>PEG</term>
<def>
<p id="Par25">Percutaneous entero-gastrostomy</p>
</def>
</def-item>
<def-item>
<term>RNS</term>
<def>
<p id="Par26">Repetitive nerve stimulation</p>
</def>
</def-item>
<def-item>
<term>SF-EMG</term>
<def>
<p id="Par27">Single-fiber electromyography</p>
</def>
</def-item>
<def-item>
<term>VAchT</term>
<def>
<p id="Par28">Vesicular acetylcholine transporter</p>
</def>
</def-item>
<def-item>
<term>WES</term>
<def>
<p id="Par29">Whole exome sequencing</p>
</def>
</def-item>
<def-item>
<term>WGS</term>
<def>
<p id="Par30">Whole genome sequencing</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>not applicable.</p>
<sec id="FPar53">
<title>Funding</title>
<p id="Par114">none received.</p>
</sec>
<sec id="FPar54" sec-type="data-availability">
<title>Availability of data and materials</title>
<p id="Par115">please contact author for data requests.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>JF was responsible for everything. The author read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar55">
<title>Ethics approval and consent to participate</title>
<p>not applicable.</p>
</sec>
<sec id="FPar56">
<title>Consent for publication</title>
<p>not applicable.</p>
</sec>
<sec id="FPar57">
<title>Competing interests</title>
<p>the author declares that he has no competing interests.</p>
</sec>
<sec id="FPar58">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sine</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment</article-title>
<source/>Lancet Neurol
          <year>2015</year>
<volume>14</volume>
<fpage>420</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="pmid">25792100</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>ZH</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pu</surname>
<given-names>CQ</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>XS</given-names>
</name>
</person-group>
<article-title>A novel AGRN mutation leads to congenital Myasthenic syndrome only affecting limb-girdle muscle</article-title>
<source/>Chin Med J
          <year>2017</year>
<volume>130</volume>
<fpage>2279</fpage>
<lpage>2282</lpage>
<pub-id pub-id-type="pmid">28937031</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bestue-Cardiel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Natera-de</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Current status of congenital myasthenic syndromes</article-title>
<source/>Rev Neurol
          <year>2017</year>
<volume>65</volume>
<fpage>161</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">28726234</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomez</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gammack</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome</article-title>
<source/>Neurology
          <year>1995</year>
<volume>45</volume>
<fpage>982</fpage>
<lpage>985</lpage>
<pub-id pub-id-type="pmid">7538206</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tsujino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Bajzer</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Udd</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Beyring</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kirkham</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2001</year>
<volume>98</volume>
<fpage>2017</fpage>
<lpage>2022</lpage>
<pub-id pub-id-type="pmid">11172068</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<mixed-citation publication-type="other">Abicht A, Müller J S, Lochmüller H. Congenital Myasthenic syndromes. 2003 may 9 [updated 2016 Jul 14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, Stephens K, Amemiya A, Ledbetter N, editors. GeneReviews® [internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK1168/">http://www.ncbi.nlm.nih.gov/books/NBK1168/</ext-link>.</mixed-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Scola</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Lorenzoni</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Werneck</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Novel synaptobrevin-1 mutation causes fatal congenital myasthenic syndrome</article-title>
<source/>Ann Clin Transl Neurol
          <year>2017</year>
<volume>4</volume>
<fpage>130</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="pmid">28168212</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodríguez Cruz</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Inherited disorders of the neuromuscular junction: an update</article-title>
<source/>J Neurol
          <year>2014</year>
<volume>261</volume>
<fpage>2234</fpage>
<lpage>2243</lpage>
<pub-id pub-id-type="pmid">25305004</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parr</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Andrew</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Finnis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jayawant</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia</article-title>
<source/>Arch Dis Child
          <year>2014</year>
<volume>99</volume>
<fpage>539</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">24500997</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mihaylova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Scola</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Gervini</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lorenzoni</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Kay</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Werneck</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Stucka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>von der Hagen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Molecular characterisation of congenital myasthenic syndromes in southern Brazil</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2010</year>
<volume>81</volume>
<fpage>973</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="pmid">20562457</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morar</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gresham</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Angelicheva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tournev</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gooding</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmuller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tordai</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kalmar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karcagi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jeanpierre</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Herczegfalvi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Venkataraman</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Warwick Carter</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Pablo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kucinskas</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Kalaydjieva</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Mutation history of the Roma/gypsies</article-title>
<source/>Am J Hum Genet
          <year>2004</year>
<volume>75</volume>
<fpage>596</fpage>
<lpage>609</lpage>
<pub-id pub-id-type="pmid">15322984</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>126th international workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands</article-title>
<source/>Neuromuscul Disord
          <year>2005</year>
<volume>15</volume>
<fpage>498</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">15951177</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A rare c.183_187dupCTCAC mutation of the acetylcholine receptor CHRNE gene in a South Asian female with congenital myasthenic syndrome: a case report</article-title>
<source/>BMC Neurol
          <year>2016</year>
<volume>16</volume>
<fpage>195</fpage>
<pub-id pub-id-type="pmid">27717316</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardissone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bernasconi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brugnoni</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome: phenotypic variability in patients harbouring p.T159P mutation in CHRNE gene</article-title>
<source/>Acta Myol
          <year>2017</year>
<volume>36</volume>
<fpage>28</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">28690392</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aharoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sadeh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shapira</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Edvardson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Daana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dor-Wollman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mimouni-Bloch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Halevy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sagie</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Argov</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rabie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spiegel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chervinsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Orenstein</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Nevo</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome in Israel: genetic and clinical characterization</article-title>
<source/>Neuromuscul Disord
          <year>2017</year>
<volume>27</volume>
<fpage>136</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">28024842</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harper</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndromes</article-title>
<source/>Semin Neurol
          <year>2004</year>
<volume>24</volume>
<fpage>111</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="pmid">15229798</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abath Neto</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Heise</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Estephan</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Mesrob</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lechner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Deleuze</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Reed</surname>
<given-names>UC</given-names>
</name>
<name>
<surname>Biancalana</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Laporte</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zanoteli</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Nonlethal CHRNA1-related congenital Myasthenic syndrome with a homozygous null mutation</article-title>
<source/>Can J Neurol Sci
          <year>2017</year>
<volume>44</volume>
<fpage>125</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">27748205</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohkawara</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mikako</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Recent advances in congenital myasthenic syndromes</article-title>
<source/>Clin Experiment Neuroimmunol
          <year>2016</year>
<volume>7</volume>
<fpage>246</fpage>
<lpage>259</lpage>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aran</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Segel</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kaneshige</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gulsuner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Renbaum</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Oliphant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meirson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Weinberg-Shukron</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hershkovitz</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zeligson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Samson</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>King</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Levy-Lahad</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome</article-title>
<source/>Neurology
          <year>2017</year>
<volume>88</volume>
<fpage>1021</fpage>
<lpage>1028</lpage>
<pub-id pub-id-type="pmid">28188302</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>O'Regan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Azuma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Laffargue</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mcmacken</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brochier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Buon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bouzidi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Topf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lacène</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Remerand</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Beaufrere</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Pebrel-Richard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thevenon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>El Chehadeh-Djebbar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Faivre</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Duffourd</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mongini</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Astrea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Burloiu</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Butoianu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sandu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Servais</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bonne</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Desguerre</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nougues</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bœuf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Laporte</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Boland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lechner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deleuze</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Strochlic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lochmuller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicole</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Impaired Presynaptic High-Affinity Choline Transporter Causes a Congenital Myasthenic Syndrome with Episodic Apnea</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>99</volume>
<fpage>753</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="pmid">27569547</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Salter</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Refai</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Barwick</surname>
<given-names>KES</given-names>
</name>
<name>
<surname>Akpulat</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Kvarnung</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chioza</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Harlalka</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Taylan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sejersen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Karakaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stüve</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Weis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Abdul-Rahman</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Chilton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blakely</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Baple</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Cirak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Choline transporter mutations in severe congenital myasthenic syndrome disrupt transporter localization</article-title>
<source/>Brain
          <year>2017</year>
<volume>140</volume>
<fpage>2838</fpage>
<lpage>2850</lpage>
<pub-id pub-id-type="pmid">29088354</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bowe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fenton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wollmann</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Choline acetyltransferase mutations in myasthenic syndrome due to deficient acetylcholine resynthesis</article-title>
<source/>Muscle Nerve
          <year>2003</year>
<volume>27</volume>
<fpage>180</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">12548525</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barisic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Paucic-Kirincic</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gazdik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lah-Tomulic</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pertl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sertic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zurak</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Clinical variability of CMS-EA (congenital myasthenic syndrome with episodic apnea) due to identical CHAT mutations in two infants</article-title>
<source/>Eur J Paediatr Neurol
          <year>2005</year>
<volume>9</volume>
<fpage>7</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">15701560</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Souza</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Batistella</surname>
<given-names>GN</given-names>
</name>
<name>
<surname>Lino</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Annes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>AS</given-names>
</name>
</person-group>
<article-title>Clinical and genetic basis of congenital myasthenic syndromes</article-title>
<source/>Arq Neuropsiquiatr
          <year>2016</year>
<volume>74</volume>
<fpage>750</fpage>
<lpage>760</lpage>
<pub-id pub-id-type="pmid">27706425</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krampfl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Voss</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Stucka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mildner</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Petrova</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Mortier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bufler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome due to a novel missense mutation in the gene encoding choline acetyltransferase</article-title>
<source/>Neuromuscul Disord
          <year>2003</year>
<volume>13</volume>
<fpage>245</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="pmid">12609506</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finlayson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Rodriguez Cruz</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Fischmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Norbury</surname>
<given-names>R</given-names>
</name>
<name>
<surname>White</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Al-Hajjar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jayawant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Yousry</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Muscle magnetic resonance imaging in congenital myasthenic syndromes</article-title>
<source/>Muscle Nerve
          <year>2016</year>
<volume>54</volume>
<fpage>211</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="pmid">26789134</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Ambang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ahmad-Annuar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rajahram</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome due to novel CHAT mutations in an ethnic kadazandusun family</article-title>
<source/>Muscle Nerve
          <year>2016</year>
<volume>53</volume>
<fpage>822</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="pmid">26789281</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Christen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Durmus</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hietala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krabetz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rodolico</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Topaloglu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Talim</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Voss</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pihko</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations</article-title>
<source/>Eur J Paediatr Neurol
          <year>2010</year>
<volume>14</volume>
<fpage>326</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="pmid">19900826</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Grady</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Verschuuren</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fock</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pride</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Best</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Benavides Damm</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>MacArthur</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Kamsteeg</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome</article-title>
<source/>Neurology
          <year>2016</year>
<volume>87</volume>
<fpage>1442</fpage>
<lpage>1448</lpage>
<pub-id pub-id-type="pmid">27590285</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability</article-title>
<source/>Neurology
          <year>2014</year>
<volume>83</volume>
<fpage>2247</fpage>
<lpage>2255</lpage>
<pub-id pub-id-type="pmid">25381298</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salpietro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Delle Vedove</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Storbeck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Efthymiou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Manole</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wiethoff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Saggar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McElreavey</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Krishnakumar</surname>
<given-names>SS</given-names>
</name>
<collab>SYNAPS Study Group</collab>
<name>
<surname>Pitt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bello</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Basel-Vanagaite</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hubshman</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Aharoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Manzur</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Wirth</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Homozygous mutations in VAMP1 cause a presynaptic congenital myasthenic syndrome</article-title>
<source/>Ann Neurol
          <year>2017</year>
<volume>81</volume>
<fpage>597</fpage>
<lpage>603</lpage>
<pub-id pub-id-type="pmid">28253535</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whittaker</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Bansagi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Lofra</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Logigian</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Sowden</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Almodovar</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Littleton</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Zuchner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome</article-title>
<source/>Neurology
          <year>2015</year>
<volume>85</volume>
<fpage>1964</fpage>
<lpage>1971</lpage>
<pub-id pub-id-type="pmid">26519543</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrmann</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sowden</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sanchez-Mejias</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Almodovar</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bansagi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pyle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boczonadi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chinnery</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Lloyd</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Littleton</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Zuchner</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-Eaton myasthenic syndrome and nonprogressive motor neuropathy</article-title>
<source/>Am J Hum Genet
          <year>2014</year>
<volume>95</volume>
<fpage>332</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="pmid">25192047</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<mixed-citation publication-type="other">Xu J, Camacho M, Xu Y, Esser V, Liu X, Trimbuch T, Pan YZ, Ma C, Tomchick DR, Rosenmund C, Rizo J. Mechanistic insights into neurotransmitter release and presynaptic plasticity from the crystal structure of Munc13–1 C(1)C(2)BMUN. Elife. 2017 Feb 8;6. pii: e22567. doi: 10.7554/eLife.22567.</mixed-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Congenital Myasthenic syndromes in 2018</article-title>
<source/>Curr Neurol Neurosci Rep
          <year>2018</year>
<volume>18</volume>
<issue>8</issue>
<fpage>46</fpage>
<pub-id pub-id-type="doi">10.1007/s11910-018-0852-4</pub-id>
<pub-id pub-id-type="pmid">29892917</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Milone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Loss of MUNC13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia</article-title>
<source/>Neurol Genet
          <year>2016</year>
<volume>2</volume>
<issue>5</issue>
<fpage>e105</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000105</pub-id>
<pub-id pub-id-type="pmid">27648472</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arredondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gochez</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Logia</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina</article-title>
<source/>Hum Genet
          <year>2014</year>
<volume>133</volume>
<fpage>599</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="pmid">24281389</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matlik</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Milhem</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Saadeldin</surname>
<given-names>IY</given-names>
</name>
<name>
<surname>Al-Jaibeji</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Al-Gazali</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family</article-title>
<source/>Pediatr Neurol
          <year>2014</year>
<volume>51</volume>
<fpage>165</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="pmid">24938146</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mihaylova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Vilchez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Salih</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kabiraj</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>D'Amico</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wölfle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schreiner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kurlemann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rasic</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Siskova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herczegfalvi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fabriciova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Weschke</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scola</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hoellen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes</article-title>
<source/>Brain
          <year>2008</year>
<volume>131</volume>
<fpage>747</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="pmid">18180250</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wargon</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kuntzer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nafissi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gaudon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lebail</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bauche</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stojkovic</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations</article-title>
<source/>Neuromuscul Disord
          <year>2012</year>
<volume>22</volume>
<fpage>318</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="pmid">22088788</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Muhaizea</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Al-Mobarak</surname>
<given-names>SB</given-names>
</name>
</person-group>
<article-title>COLQ-mutant congenital Myasthenic syndrome with microcephaly: a unique case with literature review</article-title>
<source/>Transl Neurosci
          <year>2017</year>
<volume>8</volume>
<fpage>65</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">28744372</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Shahoumi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Schwartzentruber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tarnopolsky</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Two cases of congenital myasthenic syndrome with vocal cord paralysis</article-title>
<source/>Neurology
          <year>2015</year>
<volume>84</volume>
<fpage>1281</fpage>
<lpage>1282</lpage>
<pub-id pub-id-type="pmid">25695962</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duran</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Uzunhan</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Ekici</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Çıtak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aydınlı</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Çalışkan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Severe scoliosis in a patient with COLQ mutation and congenital myasthenic syndrome: a clue for diagnosis</article-title>
<source/>Acta Neurol Belg
          <year>2013</year>
<volume>113</volume>
<fpage>531</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="pmid">23371844</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schreiner</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hoppenz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Klaeren</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Reimann</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Woelfle</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Novel COLQ mutation 950delC in synaptic congenital myasthenic syndrome and symptomatic heterozygous relatives</article-title>
<source/>Neuromuscul Disord
          <year>2007</year>
<volume>17</volume>
<fpage>262</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="pmid">17300939</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Thorburn</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Keating</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hakonarson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Christodoulou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Delayed diagnosis of congenital myasthenia due to associated mitochondrial enzyme defect</article-title>
<source/>Neuromuscul Disord
          <year>2015</year>
<volume>25</volume>
<fpage>257</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="pmid">25557462</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evangelista</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Congenital Myasthenic syndromes with predominant limb girdle weakness</article-title>
<source/>J Neuromuscul Dis
          <year>2015</year>
<volume>2</volume>
<issue>suppl 2</issue>
<fpage>S21</fpage>
<lpage>S29</lpage>
<pub-id pub-id-type="pmid">26870666</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Intra-familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations</article-title>
<source/>Dev Med Child Neurol
          <year>2010</year>
<volume>52</volume>
<fpage>e243</fpage>
<lpage>e244</lpage>
<pub-id pub-id-type="pmid">20370815</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padmanabha</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saini</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Sankhyan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Singhi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>COLQ-related congenital Myasthenic syndrome and response to salbutamol therapy</article-title>
<source/>J Clin Neuromuscul Dis
          <year>2017</year>
<volume>18</volume>
<fpage>162</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">28221310</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cagney</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Arredondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wessel</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Abdel-Hamid</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wollmann</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome</article-title>
<source/>J Med Genet
          <year>2009</year>
<volume>46</volume>
<fpage>203</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="pmid">19251977</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Luca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Crocco</surname>
<given-names>P</given-names>
</name>
<name>
<surname>De Rango</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Passarino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Association of the Laminin, alpha 5 (LAMA5) rs4925386 with height and longevity in an elderly population from southern Italy</article-title>
<source/>Mech Ageing Dev
          <year>2016</year>
<volume>155</volume>
<fpage>55</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">26968355</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Arredondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vázquez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>JX</given-names>
</name>
<collab>University of Washington Center for Mendelian Genomics</collab>
<name>
<surname>Bamshad</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nickerson</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Pytel</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Presynaptic congenital myasthenic syndrome with a homozygous sequence variant in LAMA5 combines myopia, facial tics, and failure of neuromuscular transmission</article-title>
<source/>Am J Med Genet A
          <year>2017</year>
<volume>173</volume>
<fpage>2240</fpage>
<lpage>2245</lpage>
<pub-id pub-id-type="pmid">28544784</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Logan</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rodríguez Cruz</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Martínez-Martínez</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Riepsaame</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abdelhamed</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Lake</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sewry</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jayawant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Congenital Myasthenic syndrome type 19 is caused by mutations in COL13A1, encoding the atypical non-fibrillar collagen type XIII α1 chain</article-title>
<source/>Am J Hum Genet
          <year>2015</year>
<volume>97</volume>
<fpage>878</fpage>
<lpage>885</lpage>
<pub-id pub-id-type="pmid">26626625</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tei</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Mitsuhashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishiura</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Antisense oligonucleotide-mediated exon skipping of CHRNA1 pre-mRNA as potential therapy for congenital Myasthenic syndromes</article-title>
<source/>Biochem Biophys Res Commun
          <year>2015</year>
<volume>461</volume>
<fpage>481</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="pmid">25888793</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brugnoni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maggi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Canioni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pantaleoni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>D'Arrigo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cornelio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bernasconi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mantegazza</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Identification of previously unreported mutations in CHRNA1, CHRNE and RAPSN genes in three unrelated Italian patients with congenital myasthenic syndromes</article-title>
<source/>J Neurol
          <year>2010</year>
<volume>257</volume>
<fpage>1119</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="pmid">20157724</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stricker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rupps</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pantzar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miertus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Botta</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Naretto</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Janetzki</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yaqoob</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Seelow</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fiebig</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wirth</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hoopmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Körber</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Blankenburg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mundlos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Acetylcholine receptor pathway mutations explain various fetal akinesia deformation sequence disorders</article-title>
<source/>Am J Hum Genet
          <year>2008</year>
<volume>82</volume>
<fpage>464</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="pmid">18252226</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Okuno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Milone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Otsuka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Komaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Mutations causing Slow-Channel myasthenia reveal that a valine ring in the channel pore of muscle AChR is optimized for stabilizing channel gating</article-title>
<source/>Hum Mutat
          <year>2016</year>
<volume>37</volume>
<fpage>1051</fpage>
<lpage>1059</lpage>
<pub-id pub-id-type="pmid">27375219</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<mixed-citation publication-type="other">Natera-de Benito D, Töpf A, Vilchez JJ, González-Quereda L, Domínguez-Carral J, Díaz-Manera J, Ortez C, Bestué M, Gallano P, Dusl M, Abicht A, Müller JS, Senderek J, García-Ribes A, Muelas N, Evangelista T, Azuma Y, McMacken G, Paipa Merchan A, Rodríguez Cruz PM, Camacho A, Jiménez E, Miranda-Herrero MC, Santana-Artiles A, García-Campos O, Dominguez-Rubio R, Olivé M, Colomer J, Beeson D, Lochmüller H, Nascimento A. Molecular characterization of congenital myasthenic syndromes in Spain. Neuromuscul Disord 2017. pii: S0960–8966(17)30475–3.</mixed-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Baumeister</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>S</given-names>
</name>
<name>
<surname>von der Hagen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn</article-title>
<source/>Brain
          <year>2006</year>
<volume>129</volume>
<fpage>2784</fpage>
<lpage>2793</lpage>
<pub-id pub-id-type="pmid">16916845</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sine</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Congenital myasthenia-related AChR delta subunit mutation interferes with intersubunit communication essential for channel gating</article-title>
<source/>J Clin Invest
          <year>2008</year>
<volume>118</volume>
<fpage>1867</fpage>
<lpage>1876</lpage>
<pub-id pub-id-type="pmid">18398509</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sieb</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Kraner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steinlein</surname>
<given-names>OK</given-names>
</name>
</person-group>
<article-title>Immature end-plates and utrophin deficiency in congenital myasthenic syndrome caused by epsilon-AChR subunit truncating mutations</article-title>
<source/>Hum Genet
          <year>2000</year>
<volume>107</volume>
<fpage>160</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="pmid">11030414</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gaudon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ammar</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Genin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Paturneau-Jouas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Grid</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hamri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nouioua</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tazir</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Desnuelle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barois</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chabrol</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pouget</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gouider-Khouja</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hentati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa</article-title>
<source/>Neurology
          <year>2008</year>
<volume>71</volume>
<fpage>1967</fpage>
<lpage>1972</lpage>
<pub-id pub-id-type="pmid">19064877</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faber</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Molenaar</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Vles</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Bonifati</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Verschuuren</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>van Doorn</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Kuks</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Wokke</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Baets</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>AChR deficiency due to epsilon-subunit mutations: two common mutations in the Netherlands</article-title>
<source/>J Neurol
          <year>2009</year>
<volume>256</volume>
<fpage>1719</fpage>
<lpage>1723</lpage>
<pub-id pub-id-type="pmid">19544078</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spearman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Beckstein</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sansom</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance</article-title>
<source/>Brain
          <year>2012</year>
<volume>135</volume>
<fpage>1070</fpage>
<lpage>1080</lpage>
<pub-id pub-id-type="pmid">22382357</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salih</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Oystreck</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Al-Faky</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Kabiraj</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Omer</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Subahi</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abu-Amero</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Bosley</surname>
<given-names>TM</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome due to homozygous CHRNE mutations: report of patients in Arabia</article-title>
<source/>J Neuroophthalmol
          <year>2011</year>
<volume>31</volume>
<fpage>42</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">21150643</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Edvardson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sine</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Highly fatal fast-channel syndrome caused by AChR ε subunit mutation at the agonist binding site</article-title>
<source/>Neurology
          <year>2012</year>
<volume>79</volume>
<fpage>449</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="pmid">22592360</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadeh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations</article-title>
<source/>Muscle Nerve
          <year>2011</year>
<volume>44</volume>
<fpage>289</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="pmid">21721016</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finlayson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Norwood</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Pascual-Pascual</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2013</year>
<volume>84</volume>
<fpage>1119</fpage>
<lpage>1125</lpage>
<pub-id pub-id-type="pmid">23447650</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Stricker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Megarbane</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rajab</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindner</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chouery</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Adaimy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghanem</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Delague</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Boltshauser</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Talim</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hübner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mundlos</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Escobar syndrome is a prenatal myasthenia caused by disruption of the acetylcholine receptor fetal gamma subunit</article-title>
<source/>Am J Hum Genet
          <year>2006</year>
<volume>79</volume>
<fpage>303</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="pmid">16826520</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kariminejad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Almadani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khoshaeen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Moslemi</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Tajsharghi</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Truncating CHRNG mutations associated with interfamilial variability of the severity of the Escobar variant of multiple pterygium syndrome</article-title>
<source/>BMC Genet
          <year>2016</year>
<volume>17</volume>
<fpage>71</fpage>
<pub-id pub-id-type="doi">10.1186/s12863-016-0382-5</pub-id>
<pub-id pub-id-type="pmid">27245440</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Herczegfalvi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vilchez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bachinski</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Mihaylova</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Deschauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shevell</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Soudo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hietala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aärimaa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Krahe</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Karcagi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes</article-title>
<source/>Brain
          <year>2007</year>
<volume>130</volume>
<fpage>1497</fpage>
<lpage>1506</lpage>
<pub-id pub-id-type="pmid">17439981</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergamin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hallock</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Burden</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization</article-title>
<source/>Mol Cell
          <year>2010</year>
<volume>39</volume>
<fpage>100</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">20603078</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azuma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Töpf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lorenzoni</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Roos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Viana</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kurahashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Intragenic DOK7 deletion detected by whole-genome sequencing in congenital myasthenic syndromes</article-title>
<source/>Neurol Genet
          <year>2017</year>
<volume>3</volume>
<issue>3</issue>
<fpage>e152</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000152</pub-id>
<pub-id pub-id-type="pmid">28508085</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lashley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Newsom-Davis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kennett</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jayawant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamanashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Clinical features of the DOK7 neuromuscular junction synaptopathy</article-title>
<source/>Brain
          <year>2007</year>
<volume>130</volume>
<fpage>1507</fpage>
<lpage>1515</lpage>
<pub-id pub-id-type="pmid">17452375</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jephson</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Pitt</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aloysius</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Congenital stridor with feeding difficulty as a presenting symptom of Dok7 congenital myasthenic syndrome</article-title>
<source/>Int J Pediatr Otorhinolaryngol
          <year>2010</year>
<volume>74</volume>
<fpage>991</fpage>
<lpage>994</lpage>
<pub-id pub-id-type="pmid">20554332</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srour</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bolduc</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gendron</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shevell</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mathieu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bouchard</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Brais</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>DOK7 mutations presenting as a proximal myopathy in French Canadians</article-title>
<source/>Neuromuscul Disord
          <year>2010</year>
<volume>20</volume>
<fpage>453</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="pmid">20610155</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ben Ammar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petit</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Alexandri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gaudon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rouche</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gras</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stojkovic</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lacour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petiot</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zagnoli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Viollet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Orlikowski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lazaro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stoltenburg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Paturneau-Jouas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hentati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fardeau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7</article-title>
<source/>J Neurol
          <year>2010</year>
<volume>257</volume>
<fpage>754</fpage>
<lpage>766</lpage>
<pub-id pub-id-type="pmid">20012313</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lashley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jayawant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7</article-title>
<source/>Neurology
          <year>2010</year>
<volume>74</volume>
<fpage>1517</fpage>
<lpage>1523</lpage>
<pub-id pub-id-type="pmid">20458068</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Barisic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Deschauer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lindberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Strigl-Pill</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wendt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations</article-title>
<source/>Neuromuscul Disord
          <year>2009</year>
<volume>19</volume>
<fpage>828</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="pmid">19837590</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bevilacqua</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Díaz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Campero</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vázquez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Congenital Myasthenic syndrome due to DOK7 mutations in a family from Chile</article-title>
<source/>Eur J Transl Myol
          <year>2017</year>
<volume>27</volume>
<fpage>6832</fpage>
<pub-id pub-id-type="pmid">29118959</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsao</surname>
<given-names>CY</given-names>
</name>
</person-group>
<article-title>Effective treatment with albuterol in DOK7 congenital Myasthenic syndrome in children</article-title>
<source/>Pediatr Neurol
          <year>2016</year>
<volume>54</volume>
<fpage>85</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">26552645</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Limb-girdle congenital myasthenic syndrome in a Chinese family with novel mutations in MUSK gene and literature review</article-title>
<source/>Clin Neurol Neurosurg
          <year>2016</year>
<volume>150</volume>
<fpage>41</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">27588369</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giarrana</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Joset</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sticht</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Steindl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A severe congenital myasthenic syndrome with "dropped head" caused by novel MUSK mutations</article-title>
<source/>Muscle Nerve
          <year>2015</year>
<volume>52</volume>
<fpage>668</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="pmid">25900532</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallenmüller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Müller-Felber</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stucka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Blaschek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>von der Hagen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK</article-title>
<source/>Neuromuscul Disord
          <year>2014</year>
<volume>24</volume>
<fpage>31</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">24183479</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<mixed-citation publication-type="other">Maggi L, Brugnoni R, Scaioli V, Winden TL, Morandi L, Engel AG, Mantegazza R, Bernasconi P. Marked phenotypic variability in two siblings with congenital myasthenic syndrome due to mutations in MUSK. J Neurol. 2013; [Epub ahead of print].</mixed-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Arredondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cagney</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gerke</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Soliven</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wollmann</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction</article-title>
<source/>Hum Mol Genet
          <year>2010</year>
<volume>19</volume>
<fpage>2370</fpage>
<lpage>2379</lpage>
<pub-id pub-id-type="pmid">20371544</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Connor</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Töpf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hasselmann</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Yaramis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laval</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Identification of mutations in the MYO9A gene in patients with congenital myasthenic syndrome</article-title>
<source/>Brain
          <year>2016</year>
<volume>139</volume>
<fpage>2143</fpage>
<lpage>2153</lpage>
<pub-id pub-id-type="pmid">27259756</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karakaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ceyhan-Birsoy</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Beggs</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Topaloglu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A novel missense variant in the AGRN gene; congenital Myasthenic syndrome presenting with head drop</article-title>
<source/>J Clin Neuromuscul Dis
          <year>2017</year>
<volume>18</volume>
<fpage>147</fpage>
<lpage>151</lpage>
<pub-id pub-id-type="pmid">28221305</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicole</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chaouch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Torbergsen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>de Bruyckere</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fontenille</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>van Ghelue</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Løseth</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Issop</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stålberg</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ioos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barois</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brochier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laval</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy</article-title>
<source/>Brain
          <year>2014</year>
<volume>137</volume>
<fpage>2429</fpage>
<lpage>2443</lpage>
<pub-id pub-id-type="pmid">24951643</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Stiegler</surname>
<given-names>AL</given-names>
</name>
<collab>Cameron TO</collab>
<name>
<surname>Hallock</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Dustin</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Burden</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Lrp4 is a receptor for Agrin and forms a complex with MuSK</article-title>
<source/>Cell
          <year>2008</year>
<volume>135</volume>
<fpage>334</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">18848351</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohkawara</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cabrera-Serrano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Milone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<fpage>1856</fpage>
<lpage>1868</lpage>
<pub-id pub-id-type="pmid">24234652</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tezuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Iemura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Natsume</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamanashi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Mesdc2 plays a key role in cell-surface expression of Lrp4 and postsynaptic specialization in myotubes</article-title>
<source/>FEBS Lett
          <year>2013</year>
<volume>587</volume>
<fpage>3749</fpage>
<lpage>3754</lpage>
<pub-id pub-id-type="pmid">24140340</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ohkawara</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Impaired synaptic development, maintenance, and neuromuscular transmission in LRP4-related myasthenia</article-title>
<source/>JAMA Neurol
          <year>2015</year>
<volume>72</volume>
<fpage>889</fpage>
<lpage>896</lpage>
<pub-id pub-id-type="pmid">26052878</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Régal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Verhille</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Meulemans</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Creemers</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<fpage>1254</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="pmid">24610330</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habbout</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rivier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Giuliano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Echenne</surname>
<given-names>B</given-names>
</name>
<name>
<surname>King</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Männikkö</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chahine</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nicole</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bendahhou</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A recessive Nav1.4 mutation underlies congenital myasthenic syndrome with periodic paralysis</article-title>
<source/>Neurology
          <year>2016</year>
<volume>86</volume>
<fpage>161</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="pmid">26659129</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kassar</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Quick</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klassen</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kissel</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Lossin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome</article-title>
<source/>Ann Neurol
          <year>2015</year>
<volume>77</volume>
<fpage>840</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="pmid">25707578</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsujino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maertens</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Myasthenic syndrome caused by mutation of the SCN4A sodium channel</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2003</year>
<volume>100</volume>
<fpage>7377</fpage>
<lpage>7382</lpage>
<pub-id pub-id-type="pmid">12766226</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natera-de Benito</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bestué</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vilchez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Töpf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>García-Ribes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Trujillo-Tiebas</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>García-Hoyos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ortez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Camacho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jiménez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations</article-title>
<source/>Neuromuscul Disord
          <year>2016</year>
<volume>26</volume>
<fpage>153</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">26782015</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dris</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schnier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cockrell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wollmann</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome caused by two non-N88K rapsyn mutations</article-title>
<source/>Clin Genet
          <year>2007</year>
<volume>72</volume>
<fpage>63</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">17594401</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Milone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Iannaccone</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Myasthenic syndrome due to defects in rapsyn: clinical and molecular findings in 39 patients</article-title>
<source/>Neurology
          <year>2009</year>
<volume>73</volume>
<fpage>228</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="pmid">19620612</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>CY</given-names>
</name>
</person-group>
<article-title>Limb girdle myasthenia with digenic RAPSN and a novel disease gene AK9 mutations</article-title>
<source/>Eur J Hum Genet
          <year>2017</year>
<volume>25</volume>
<fpage>192</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">27966543</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<mixed-citation publication-type="other">Pavone P, Praticò AD, Pavone V, Falsaperla R. Congenital familial myasthenic syndromes: disease and course in an affected dizygotic twin pair. BMJ Case Rep 2013;2013. pii: bcr2012007651. doi: 10.1136/bcr-2012-007651.</mixed-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visser</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Laughlin</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Litchy</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Benarroch</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Milone</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Rapsyn congenital myasthenic syndrome worsened by fluoxetine</article-title>
<source/>Muscle Nerve
          <year>2017</year>
<volume>55</volume>
<fpage>131</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">27397848</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentili</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ansaloni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morello</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cecini</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Cordelli</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Baroncini</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Diagnosis of congenital myasthenic syndrome with mutation of the RAPSN gene after general anaesthesia</article-title>
<source/>Eur J Anaesthesiol
          <year>2011</year>
<volume>28</volume>
<fpage>748</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="pmid">21372719</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forrest</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mellerio</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dopping-Hepenstal</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>McGrath</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Buk</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Al-Sarraj</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wraige</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jungbluth</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Congenital muscular dystrophy, myasthenic symptoms and epidermolysis bullosa simplex (EBS) associated with mutations in the PLEC1 gene encoding plectin</article-title>
<source/>Neuromuscul Disord
          <year>2010</year>
<volume>20</volume>
<fpage>709</fpage>
<lpage>711</lpage>
<pub-id pub-id-type="pmid">20624679</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Arredondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cagney</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Mozaffar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yousif</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Gregg</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Sivak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Konia</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wollmann</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE</article-title>
<source/>Clin Genet
          <year>2011</year>
<volume>80</volume>
<fpage>444</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">21175599</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Juel</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Hobson-Webb</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Stickler</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Bite</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Myasthenic syndrome caused by plectinopathy</article-title>
<source/>Neurology
          <year>2011</year>
<volume>76</volume>
<fpage>327</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">21263134</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaouch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Porcelli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Edvardson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scarcia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>De Grassi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Laval</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Töpf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huebner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>von der Hagen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Elpeleg</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Mutations in the mitochondrial citrate carrier SLC25A1 are associated with impaired neuromuscular transmission</article-title>
<source/>J Neuromuscul Dis
          <year>2014</year>
<volume>1</volume>
<fpage>75</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">26870663</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hicks</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Salih</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Finlayson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carboni</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zoltowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Farsani</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Laval</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seidhamed</surname>
<given-names>MZ</given-names>
</name>
<collab>WGS500 Consortium</collab>
<name>
<surname>Donnelly</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bentley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>SJ</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndromes due to mutations in ALG2 and ALG14</article-title>
<source/>Brain
          <year>2013</year>
<volume>136</volume>
<fpage>944</fpage>
<lpage>956</lpage>
<pub-id pub-id-type="pmid">23404334</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rodríguez Cruz</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McGowan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Farrugia</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Petty</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Sedghi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Basiri</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Sarkozy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bertoli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pitt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kennett</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Parton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies</article-title>
<source/>Brain
          <year>2015</year>
<volume>138</volume>
<fpage>2493</fpage>
<lpage>2504</lpage>
<pub-id pub-id-type="pmid">26133662</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoltowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Finlayson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR</article-title>
<source/>Hum Mol Genet
          <year>2013</year>
<volume>22</volume>
<fpage>2905</fpage>
<lpage>2913</lpage>
<pub-id pub-id-type="pmid">23569079</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Pertl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stucka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>David</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>A 3'-UTR mutation creates a microRNA target site in the GFPT1 gene of patients with congenital myasthenic syndrome</article-title>
<source/>Hum Mol Genet
          <year>2015</year>
<volume>24</volume>
<fpage>3418</fpage>
<lpage>3426</lpage>
<pub-id pub-id-type="pmid">25765662</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vellieux</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fontenille</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>De Bruyckere</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Davoine</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Brochier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Messéant</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fardeau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lacène</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Streichenberger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Manel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lacour</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nadaj-Pakleza</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sukno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bouhour</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Laforêt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fontaine</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Strochlic</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chevessier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stojkovic</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nicole</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mutations in GFPT1-related congenital myasthenic syndromes are associated with synaptic morphological defects and underlie a tubular aggregate myopathy with synaptopathy</article-title>
<source/>J Neurol
          <year>2017</year>
<volume>264</volume>
<fpage>1791</fpage>
<lpage>1803</lpage>
<pub-id pub-id-type="pmid">28712002</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basiri</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sedghi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Clinical features in a large Iranian family with a limb-girdle congenital myasthenic syndrome due to a mutation in DPAGT1</article-title>
<source/>Neuromuscul Disord
          <year>2013</year>
<volume>23</volume>
<fpage>469</fpage>
<lpage>472</lpage>
<pub-id pub-id-type="pmid">23591138</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Oldfors</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindbergh</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mallebrera</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vilchez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Muelas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kirschner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nafissi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kariminejad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nilipour</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bozorgmehr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Najmabadi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rodolico</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sieb</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schlotter</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schoser</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Voit</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Steinlein</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Najafi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Urtizberea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Chaouch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations</article-title>
<source/>J Neurol
          <year>2012</year>
<volume>259</volume>
<fpage>838</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="pmid">21975507</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maselli</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Arredondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ngo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Stajich</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wollmann</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia</article-title>
<source/>Clin Genet
          <year>2014</year>
<volume>85</volume>
<fpage>166</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="pmid">23488891</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huh</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Limb-girdle myasthenia with tubular aggregates associated with novel GFPT1 mutations</article-title>
<source/>Muscle Nerve
          <year>2012</year>
<volume>46</volume>
<fpage>600</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="pmid">22987706</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jensen</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Willer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saade</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Mozaffar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Scavina</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stefans</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Winder</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>KD</given-names>
</name>
</person-group>
<article-title>GMPPB-associated Dystroglycanopathy: emerging common variants with phenotype correlation</article-title>
<source/>Hum Mutat
          <year>2015</year>
<volume>36</volume>
<fpage>1159</fpage>
<lpage>1163</lpage>
<pub-id pub-id-type="pmid">26310427</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Novel mutations in the C-terminal region of GMPPB causing limb-girdle muscular dystrophy overlapping with congenital myasthenic syndrome</article-title>
<source/>Neuromuscul Disord
          <year>2017</year>
<volume>27</volume>
<fpage>557</fpage>
<lpage>564</lpage>
<pub-id pub-id-type="pmid">28433477</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodríguez Cruz</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Basiri</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sedghi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Farrugia</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Holton</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Petty</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Kennett</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pitt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sarkozy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Muntoni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Clinical features of the myasthenic syndrome arising from mutations in GMPPB</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>2016</year>
<volume>87</volume>
<fpage>802</fpage>
<lpage>809</lpage>
<pub-id pub-id-type="pmid">27147698</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montagnese</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Klupp</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Karampinos</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Biskup</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gläser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kirschke</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Schoser</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Two patients with GMPPB mutation: the overlapping phenotypes of limb-girdle myasthenic syndrome and limb-girdle muscular dystrophy dystroglycanopathy</article-title>
<source/>Muscle Nerve
          <year>2017</year>
<volume>56</volume>
<fpage>334</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="pmid">27874200</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monies</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Al-Hindi</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Al-Muhaizea</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Jaroudi</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Al-Younes</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Naim</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Wakil</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Bohlega</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Clinical and pathological heterogeneity of a congenital disorder of glycosylation manifesting as a myasthenic/myopathic syndrome</article-title>
<source/>Neuromuscul Disord
          <year>2014</year>
<volume>24</volume>
<fpage>353</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">24461433</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<mixed-citation publication-type="other">Schorling DC, Rost S, Lefeber DJ, Brady L, Müller CR, Korinthenberg R, Tarnopolsky M, Bönnemann CG, Rodenburg RJ, Bugiani M, Beytia M, Krüger M, van der Knaap M, Kirschner J. Early and lethal neurodegeneration with myasthenic and myopathic features: A new ALG14-CDG. Neurology 2017 . pii: 10.1212/WNL.0000000000004234. doi: 10.1212/WNL.0000000000004234.</mixed-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Finlayson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Slater</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McGowan</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Maslau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Twigg</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Pascual Pascual</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates</article-title>
<source/>Am J Hum Genet
          <year>2012</year>
<volume>91</volume>
<fpage>193</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="pmid">22742743</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selcen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Stans</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Wieben</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>DPAGT1 myasthenia and myopathy: genetic, phenotypic, and expression studies</article-title>
<source/>Neurology
          <year>2014</year>
<volume>82</volume>
<fpage>1822</fpage>
<lpage>1830</lpage>
<pub-id pub-id-type="pmid">24759841</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Robb</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rushing</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Belaya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndrome caused by mutations in DPAGT</article-title>
<source/>Neuromuscul Disord
          <year>2015</year>
<volume>25</volume>
<fpage>253</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="pmid">25500013</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodríguez Cruz</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Sewry</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jayawant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Squier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>McWilliam</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Congenital myopathies with secondary neuromuscular transmission defects; a case report and review of the literature</article-title>
<source/>Neuromuscul Disord
          <year>2014</year>
<volume>24</volume>
<fpage>1103</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="pmid">25127990</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Grozeva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Kogelenberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>NY</given-names>
</name>
<name>
<surname>Pike</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hurles</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Baldeweg</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kurian</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Cousin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>FL</given-names>
</name>
</person-group>
<article-title>Identification of a human synaptotagmin-1 mutation that perturbs synaptic vesicle cycling</article-title>
<source/>J Clin Invest
          <year>2015</year>
<volume>125</volume>
<fpage>1670</fpage>
<lpage>1678</lpage>
<pub-id pub-id-type="pmid">25705886</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shields</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Fulcer</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bollig</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Rock</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Vrailas-Mortimer</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Reist</surname>
<given-names>NE</given-names>
</name>
</person-group>
<article-title>Drosophila studies support a role for a presynaptic synaptotagmin mutation in a human congenital myasthenic syndrome</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<issue>9</issue>
<fpage>e0184817</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0184817</pub-id>
<pub-id pub-id-type="pmid">28953919</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation</article-title>
<source/>Rev Neurol (Paris)
          <year>2004</year>
<volume>160</volume>
<fpage>163</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">15034473</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<mixed-citation publication-type="other">LoRusso SJ, Iyadurai SJ. Decrement with high frequency repetitive nerve stimulation in a RAPSN congenital myasthenic syndrome. Muscle Nerve. 2017. 10.1002/mus.25995.</mixed-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caggiano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khirani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Verrillo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Barnerias</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amaddeo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gitiaux</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thierry</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Desguerre</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cutrera</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fauroux</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Sleep in infants with congenital myasthenic syndromes</article-title>
<source/>Eur J Paediatr Neurol
          <year>2017</year>
<volume>21</volume>
<fpage>842</fpage>
<lpage>851</lpage>
<pub-id pub-id-type="pmid">28755803</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaouch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schara</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Rakocević-Stojanović</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lindberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Scola</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Werneck</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vilchez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Muelas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Argov</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome</article-title>
<source/>J Neurol
          <year>2012</year>
<volume>259</volume>
<fpage>474</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="pmid">21822932</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nazim</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nasrin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Splicing regulation and dysregulation of cholinergic genes expressed at the neuromuscular junction</article-title>
<source/>J Neurochem
          <year>2017</year>
<volume>142</volume>
<issue>suppl 2</issue>
<fpage>64</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">28072465</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stojkovic</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nicole</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Béhin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laforêt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Servais</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fardeau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Membres du réseau national Syndromes Myasthéniques Congénitaux. Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy - the French National Congenital Myasthenic Syndrome Network experience</article-title>
<source/>Rev Neurol (Paris)
          <year>2013</year>
<volume>169</volume>
<issue>suppl 1</issue>
<fpage>S45</fpage>
<lpage>S55</lpage>
<pub-id pub-id-type="pmid">23452772</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Servais</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Baudoin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zehrouni</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Stojkovic</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Pregnancy in congenital myasthenic syndrome</article-title>
<source/>J Neurol
          <year>2013</year>
<volume>260</volume>
<fpage>815</fpage>
<lpage>819</lpage>
<pub-id pub-id-type="pmid">23108489</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tsujino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1998</year>
<volume>95</volume>
<fpage>9654</fpage>
<lpage>9659</lpage>
<pub-id pub-id-type="pmid">9689136</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sadeh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Blatt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brengman</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>E-box mutations in the RAPSN promoter region in eight cases with congenital myasthenic syndrome</article-title>
<source/>Hum Mol Genet
          <year>2003</year>
<volume>12</volume>
<fpage>739</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="pmid">12651869</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chevessier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Faraut</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ravel-Chapuis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gaudon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Prioleau</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Herbst</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goillot</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ioos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Azulay</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Attarian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leroy</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Legay</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schaeffer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fardeau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pouget</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Towards the molecular elucidation of congenital myasthenic syndromes: identification of mutations in MuSK</article-title>
<source/>Acta Myol
          <year>2005</year>
<volume>24</volume>
<fpage>55</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="pmid">16550915</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Spearman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Newsom-Davis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fawcett</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Motomura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Slater</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamanashi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Dok-7 mutations underlie a neuromuscular junction synaptopathy</article-title>
<source/>Science
          <year>2006</year>
<volume>313</volume>
<fpage>1975</fpage>
<lpage>1978</lpage>
<pub-id pub-id-type="pmid">16917026</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huzé</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bauché</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Richard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chevessier</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Goillot</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gaudon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ben Ammar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chaboud</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grosjean</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lecuyer</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rouche</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alexandri</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kuntzer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fardeau</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brancaccio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rüegg</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eymard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schaeffer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hantaï</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Identification of an agrin mutation that causes congenital myasthenia and affects synapse function</article-title>
<source/>Am J Hum Genet
          <year>2009</year>
<volume>85</volume>
<fpage>155</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="pmid">19631309</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senderek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Dusl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Strom</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Guergueltcheva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Diepolder</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Laval</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Maxwell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cossins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muelas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vilchez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Colomer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mallebrera</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nafissi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kariminejad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nilipour</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bozorgmehr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Najmabadi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rodolico</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sieb</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Steinlein</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Schlotter</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schoser</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kirschner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Voit</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oldfors</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lindbergh</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Urtizberea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>von der Hagen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hübner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Palace</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bushby</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Beeson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Abicht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lochmüller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect</article-title>
<source/>Am J Hum Genet
          <year>2011</year>
<volume>88</volume>
<fpage>162</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="pmid">21310273</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<mixed-citation publication-type="other">Rodríguez Cruz PM, Palace J, Beeson D. The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes. Int J Mol Sci 2018 ;19(6). pii: E1677. doi: 10.3390/ijms19061677.</mixed-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<mixed-citation publication-type="other">Souza PV, Batistella GN, Lino VC, Pinto WB, Annes M, Oliveira AS. Clinical and genetic basis of congenital myasthenic syndromes. Arq Neuropsiquiatr 2016;74:750–760.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>